Novel cell line and uses thereof

The SenzaCell cell line addresses the challenges of using primary DCs by providing a reliable in vitro assay for predicting sensitization and allergenicity through biomarker expression analysis, enhancing the accuracy and efficiency of chemical and protein testing.

CA3074791CActive Publication Date: 2026-11-10SENZAGEN
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CA3074791
Authority / Receiving Office
CA · CA
Patent Type
Patents
Current Assignee / Owner
Priority Date
2017-09-25
Filing Date
2018-09-24
Publication Date
2026-11-10
Estimated Expiration
2038-09-24

AI Technical Summary

Technical Problem

The multifaceted phenotypes and specialized functions of different dendritic cell subpopulations, along with their wide and scarce distribution, complicate the use of primary DCs as a test platform for predicting sensitization to chemicals and proteins, necessitating the development of accurate and reliable in vitro assays that circumvent the variability and difficulty in obtaining primary DCs.

Method used

A non-naturally occurring dendritic-like myeloid leukemia cell line, termed 'SenzaCell', is developed and utilized in the Genomic Allergen Rapid Detection (GARD) assay to predict the sensitizing or allergenic potential of test agents by measuring the expression of specific biomarkers.

Benefits of technology

The SenzaCell line provides a reliable and consistent platform for identifying agents capable of inducing sensitization and allergenicity, offering a more accurate and efficient alternative to primary DCs by leveraging its phenotypic and transcriptional profiles.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention provides a non-naturally occurring dendritic-like myeloid leukaemia cell according to ATCC Patent Deposit Designation PTA-123875, and methods and kits utilising such cells.
Need to check novelty before this filing date? Find Prior Art

Description

NOVEL CELL LINE AND USES THEREOF Field of Invention The present invention provides a non-naturally occurring dendritic-like cell line and methods and kits utilising such cells. Background Dendritic cells (DCs) play key roles in the immune response by bridging the essential connections between innate and adaptive immunity. They can, upon triggering, rapidly produce large amounts of mediators, which influence migration and activation of other cells at the site of inflammation, and selectively respond to various pathogens and environmental factors, by fine-tuning the cellular response through antigen-presentation. Thus, exploring and utilizing the immunological decision-making by DCs during stimulation with sensitizers, can serve as a potent test strategy for prediction of sensitization. However, multifaceted phenotypes and specialized functions of different DC subpopulations, as well as their wide and scarce distribution, are complicating factors, which impede the employment of primary DCs as a test platform. Hence, there is a real need to establish accurate and reliable in vitro assays that also circumvent the problems associated with variability of and difficulty in obtaining primary DCs, such as by utilising dendritic-like model cell lines. The Genomic Allergen Rapid Detection (GARD) is an in vitro assay developed for the assessment of chemical and protein sensitizers and allergens. It uses transcriptional profiles from a dendritic cell-like cell line, to predict the sensitizing or allergenic potential of test agents (9). The transcriptional profiles consist of genes that were identified as having the greatest predicting performance in distinguishing sensitizers from non-sensitizers. Specifically, GARD has been developed to identify: skin sensitizers (WO 2012 / 056236; Johansson et al. (2017) Evaluation of the GARD assay in a blind Cosmetics Europe study. ALTEX Online first February 17, 2017; Forreryd et al. (2016) From genome-wide arrays to tailor-made biomarker readout – Progress towards routine analysis of skin sensitizing chemicals with GARD. Toxicolgy In Vitro; Johansson et al. (2014) GARD in- house validation – A proof of concept. Tox Sci; Johansson et al., (2011) A genomic biomarker signature can predict skin sensitizers using a cell-based in vitro alternative to animal tests. BMC Genomics, 2011); respiratory sensitizers (WO 2013 / 160882; WO 2016 / 083604; Forreryd et al. (2015) Prediction of chemical Respiratory sensitizers using GARD, a novel in vitro assay based on a genomic biomarker signature. PLoS One 10(3)); the potency of skin sensitizers (PCT / EP2017 / 056878; Zeller et al. (2017) The GARD platform for potency assessment of skin sensitizing chemicals. ALTEX Online first published April 12, 2017, version 2); and the allergenicity of proteins. Summary of Invention The inventors now provide a non-naturally occurring dendritic-like myeloid leukemia cell line termed "SenzaCell" (ATCC Patent Deposit Designation PTA-123875) as a preferred dendritic cell-like cell line suitable for use in GARD assays. SenzaCell has been compared to the MUTZ-3 cell line which may also be used in GARD assays; MUTZ-3 cells are dendritic-like cells available from Deutsche Sammlung für Mikroorganismen und Zellkulturen GmbH (DSMZ), Braunschweig, Germany (www.dsmz.de; DSMZ No. ACC 295). MUTZ-3 cells are however protocolled to require culture with a feeder cell line which complicates their use. Therefore, there remains a need for alternatives to MUTZ-3 for use in methods such as the GARD assays. The comparison between SenzaCell and MUTZ-3 included a phenotypic analysis where the expression of a panel of biomarkers were compared, a transcriptional analysis where the transcription levels of the cell lines were compared, a comparison of their DNA sequences and a functional analysis, which revealed many quantifiable differences in the phenotype and transcriptional profiles and yet showed shared functionality in the GARD assays. Therefore, in a first aspect of the invention there is provided a non-naturally occurring dendritic-like myeloid leukaemia cell according to ATCC Patent Deposit Designation PTA- 123875. The cell is also referred to herein as "SenzaCell". SenzaCell (ATCC Patent Deposit Designation PTA-123875) was deposited at the American Type Culture Collection (ATCC), 10801 University Blvd, Manassas, VA 20110, USA, by SenzaGen AB on 9 March 2017. By "non-naturally occurring", we mean that the cell is different to, modified from, and / or a variant of, those which would be found in nature; in other words, they are not cells which would normally occur in nature. For example, different to, modified from, and / or a variant of, a naturally occurring human myeloid leukaemia cell or a naturally occurring dendritic cell. In a second aspect of the invention there is provided a cell culture comprising a population of cells according to the first aspect. In one embodiment the cell or population of cells comprises or consists of immortal or immortalised cells. By "immortal" we mean cells that are not limited by a point at which they can no longer continue to divide, which might otherwise be due to DNA damage or shortened telomeres. In an additional or alternative embodiment the cell or population of cells comprises or consists of undifferentiated cells. In a third aspect of the invention there is provided an in vitro method for identifying agents capable of inducing sensitization and / or allergenicity in a mammal comprising or consisting of the steps of: a) exposing a population of the dendritic-like cells according to the first or second aspect to a test agent; and b) measuring in the cells the expression of one or more biomarker(s) selected from the group defined in one or more of Tables A, B, C, D, and E; wherein the expression in the cells of the one or more biomarkers measured in step (b) is indicative of the sensitizing and / or allergenic effect of the test agent. In a fourth aspect of the invention there is provided an in vitro method for identifying agents capable of inducing sensitization of mammalian skin comprising or consisting of the steps of: a) exposing a population of the dendritic-like cells according to the first or second aspect to a test agent; and b) measuring in the cells the expression of one or more biomarker(s) selected from the group defined in Table A; wherein the expression in the cells of the one or more biomarkers measured in step (b) is indicative of the skin sensitizing effect of the test agent. Methods for identifying agents capable of inducing sensitization of mammalian skin which may use the dendritic-like cells according to the invention are described in the functional analysis section of Example 1. The methods described in WO 2012 / 056236; Johansson et al. (2017) Evaluation of the GARD assay in a blind Cosmetics Europe study. ALTEX Online first February 17, 2017; Forreryd et al. (2016) From genome-wide arrays to tailor- made biomarker readout – Progress towards routine analysis of skin sensitizing chemicals with GARD. Toxicolgy In Vitro; Johansson et al. (2014) GARD in-house validation – A proof of concept. Tox Sci; Johansson et al., (2011) A genomic biomarker signature can predict skin sensitizers using a cell-based in vitro alternative to animal tests. BMC Genomics, 2011, may also be used. In one embodiment, the method is for identifying agents capable of inducing a hypersensitivity response in human skin. Preferably, the hypersensitivity response is a cell-mediated hypersensitivity response, for example, a Type IV hypersensitivity response. Preferably, the hypersensitivity response is a Type IV delayed-type hypersensitivity reaction in a mammal. Preferably, the Type IV delayed-type hypersensitivity reaction is DC-mediated. Preferably, the method is for identifying agents capable of inducing allergic contact dermatitis (ACD) (i.e. the hypersensitivity response is ACD). In one embodiment, the "agents capable of inducing sensitization of mammalian skin" is an agent capable of inducing and triggering a Type IV delayed-type hypersensitivity reaction at a site of epidermal contact in a mammal. In a fifth aspect of the invention there is provided a method for identifying agents capable of inducing respiratory sensitization in a mammal comprising or consisting of the steps of: a) exposing a population of the dendritic-like cells according to the first or second aspect to a test agent; and b) measuring in the cells the expression of one or more biomarker(s) selected from the group defined in Table B; wherein the expression in the cells of the one or more biomarkers measured in step (b) is indicative of the respiratory sensitizing effect of the test agent. In a sixth aspect of the invention there is provided a method for identifying agents capable of inducing respiratory sensitization in a mammal comprising or consisting of the steps of: a) exposing a population of the dendritic-like cells according to the first or second aspect to a test agent; and b) measuring in the cells the expression of one or more biomarker(s) selected from the group defined in Table C; wherein the expression in the cells of the one or more biomarkers measured in step (b) is indicative of the respiratory sensitizing effect of the test agent. The methods of the fifth and sixth aspects may be combined such that step (b) comprises measuring in the cells the expression of one or more biomarker(s) selected from the group defined in Tables B and / or C. Methods for identifying agents capable of inducing respiratory sensitization in a mammal which may use the dendritic-like cells according to the invention are discussed in Example 2. The methods described in WO 2013 / 160882; WO 2016 / 083604; and Forreryd et al. (2015) Prediction of chemical Respiratory sensitizers using GARD, a novel in vitro assay based on a genomic biomarker signature. PLoS One 10(3), may also be used. By "agents capable of inducing respiratory sensitization" we mean any agent capable of inducing and triggering a Type I immediate hypersensitivity reaction in the respiratory tract of a mammal. Preferably, the Type I immediate hypersensitivity reaction is DC-mediated and / or involves the differentiation of T cells into Th2 cells. Preferably the Type I immediate hypersensitivity reaction results in humoral immunity and / or respiratory allergy. In one embodiment, the "agents capable of inducing sensitization of mammalian skin" is an agent capable of inducing and triggering a Type I immediate hypersensitivity reaction at a site of lung epithelium in a mammal. Preferably, the site of lung epithelium is in the respiratory zone of the lung, but may alternatively or additionally be in the conductive zone of the lung. In a seventh aspect of the invention there is provided a method for determining the skin sensitizing potency of an agent comprising or consisting of the steps of: (a) providing a population of the dendritic-like cells according to the first or second aspect; (b) exposing the cells provided in step (a) to a test agent; and (c) measuring in the cells of step (b) the expression of one or more biomarkers selected from the group defined in Table D; wherein the expression of the one or more biomarkers measured in step (c) is indicative of the skin sensitizing potency of the test agent of step (b). Methods for determining the skin sensitizing potency of an agent which may use the dendritic-like cells according to the invention are discussed in Example 3. The methods described in Zeller et al. (2017), The GARD platform for potency assessment of skin sensitizing chemicals. ALTEX Online first published April 12, 2017, version 2 and PCT / EP2017 / 056878, may also be used. In an eighth aspect of the invention there is provided a method for identifying proteins which are allergenic in a mammal comprising or consisting of the steps of: (a) providing a population of the dendritic-like cells according to the first or second aspect; (b) exposing the cells provided in step (a) to a test protein; and (c) measuring in the cells of step (b) the expression of one or more biomarkers selected from the group defined in Table E; wherein the expression of the one or more biomarkers measured in step (c) is indicative of the allergenicity of the test protein of step (b). Methods for identifying proteins which are allergenic in a mammal which may use the dendritic-like cells according to the invention are discussed in detail in Example 4. In one embodiment the method according to any aspect of the invention further comprises: d) exposing a separate population of the dendritic-like cells according to the first or second aspect to one or more negative control agent that does not induce sensitization and / or allergy in a mammal; and e) measuring in the cells of step (d) the expression of the one or more biomarkers measured in step (b) or (c) wherein the test agent is identified as a sensitizer and / or as allergenic in the event that the expression of the one or more biomarkers measured in step (e) differs from the expression of the one or more biomarkers measured in step (b) or (c). A vehicle control may be used as the negative control agent. The vehicle control may comprise DMSO and / or distilled water. In an additional or alternative embodiment unstimulated cells may be used as the negative control. By "unstimulated cells" we include or mean cells which have not been exposed to a specific test agent. In an additional or alternative embodiment the one or more negative control agent may comprise or consist of one or more agent selected from the group consisting of 1-Butanol; 2-Aminophenol; 2-Hydroxyethyl acrylate; 2-nitro-1,4-Phenylenediamine; 4-Aminobenzoic acid; Chlorobenzene; Dimethyl formamide; Ethyl vanillin; Formaldehyde; Geraniol; Hexylcinnamic aldehyde; Isopropanol; Kathon CG*; Methyl salicylate; Penicillin G; Propylene glycol; Potassium Dichromate; Potassium permanganate; Tween 80; and Zinc sulphate. In an additional or alternative embodiment the expression of the one or more biomarkers measured in step (b) or (c) is measured in the cells provided in step (a) prior to and following exposure to the test agent, and wherein the difference in expression between the one or more biomarkers prior to and following exposure to the test agent is indicative of the allergenicity and / or sensitizing effect of the test agent. Hence, the cells provided in step (a) may provide both the negative control and the test result. By "differs from the expression of the one or more biomarkers measured in step (b) or (c)" and "difference in expression" we include that the presence and or amount in a first sample (e.g., a test agent sample) differs from that of a second sample (e.g., a control agent sample). For example, the presence and / or amount in the test sample may differ from that of the one or more negative control sample in a statistically significant manner. Preferably the expression of the one or more biomarkers in the cell population exposed to the test agent is: less than or equal to 80% of that of the cell population exposed to the negative control agent, for example, no more than 79%, 78%, 77%, 76%, 75%, 74%, 73%, 72%, 71%, 70%, 69%, 68%, 67%, 66%, 65%, 64%, 63%, 62%, 61%, 60%, 59%, 58%, 57%, 56%, 55%, 54%, 53%, 52%, 51%, 50%, 49%, 48%, 47%, 46%, 45%, 44%, 43%, 42%, 41%, 40%, 39%, 38%, 37%, 36%, 35%, 34%, 33%, 32%, 31%, 30%, 29%, 28%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or 0% of that of the cell population exposed to the negative control or negative control agent; or at least 120% of that of the cell population exposed to the negative control agent, for example, at least 121%, 122%, 123%, 124%, 125%, 126%, 127%, 128%, 129%, 130%, 131%, 132%, 133%, 134%, 135%, 136%, 137%, 138%, 139%, 140%, 141%, 142%, 143%, 144%, 145%, 146%, 147%, 148%, 149%, 150%, 151%, 152%, 153%, 154%, 155%, 156%, 157%, 158%, 159%, 160%, 161%, 162%, 163%, 164%, 165%, 166%, 167%, 168%, 169%, 170%, 171%, 172%, 173%, 174%, 175%, 176%, 177%, 178%, 179%, 180%, 181%, 182%, 183%, 184%, 185%, 186%, 187%, 188%, 189%, 190%, 191%, 192%, 193%, 194%, 195%, 196%, 197%, 198%, 199%, 200%, 225%, 250%, 275%, 300%, 325%, 350%, 375%, 400%, 425%, 450%, 475% or at least 500% of that of the cell population exposed to the negative control or negative control agent By "differs from the expression of the one or more biomarkers measured in step (b) or (c)" we alternatively or additionally include that the test sample is classified as belonging to a different group as the one or more negative control sample. For example, where an SVM is used, the test sample is on the other side of the decision value threshold as the one or more negative control sample (e.g., if the test agent is classified as a protein allergen if one or more test (or replicate thereof) has an SVM decision value of ≤0, then the one or more positive control samples (or the majority thereof) should also have an SVM decision value of ≤0). In an additional or alternative embodiment the method according to any aspect of the invention further comprises: f) exposing a separate population of the dendritic-like cells according to the first or second aspect to one or more positive control agent that induces sensitization and / or is allergenic in a mammal; and g) measuring in the cells of step (f) the expression of the one or more biomarkers measured in step (b) or (c) wherein the test agent is identified as a sensitizer and / or as allergenic in the event that the expression of the one or more biomarkers measured in step (f) corresponds to the expression of the one or more biomarkers measured in step (b) or (c). In an additional or alternative embodiment, the one or more positive control agent provided in step (f) comprises or consists of one or more agent selected from the group consisting of: Der p 1; and Der p 7. In an additional or alternative embodiment, the one or more positive control agent may comprise or consist of one or more agent selected from the group consisting of Ammonium hexachloroplatinate; Ammonium persulfate; Ethylenediamine; Glutaraldehyde; Hexamethylen diisocyanate; Maleic Anhydride; Methylene diphenol diisocyanate; Phtalic Anhydride; Toluendiisocyanate; and Trimellitic anhydride. By "corresponds to the expression of the one or more biomarkers measured in step (b) or (c)" we mean the expression of the one or more biomarkers in the cell population exposed to the test agent is identical to, or does not differ significantly from, that of the cell population exposed to the one more positive control agent. Preferably the expression of the one or more biomarkers in the cell population exposed to the test agent is between 81% and 119% of that of the cell population exposed to the one more positive control agent, for example, greater than or equal to 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% of that of the cell population exposed to the one more positive control agent, and less than or equal to 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 110%, 111%, 112%, 113%, 114%, 115%, 116%, 117%, 118% or 119% of that of the cell population exposed to the one more positive control agent. By "corresponds to the expression of the one or more biomarkers measured in step (b) or (c)" we alternatively or additionally include that the test sample is classified as belonging to the same group as the one or more positive control sample. For example, where an SVM is used, the test sample is on the same side of the decision value threshold as the one or more positive control sample (e.g., if the test agent is classified as allergenic if one or more test (or replicate thereof) has an SVM decision value of >0, then the one or more positive control samples (or the majority thereof) should also have an SVM decision value of <com:Math><semantics>>0<annotation encoding="application / x-tex">>0< / annotation>< / semantics>< / com:Math>). In an additional or alternative embodiment, the method is indicative of the allergenic and / or sensitizing potency of the agent to be tested. For example, the method may be used to predict the relative allergenic and / or sensitizing potency of a test agent compared to a positive control and / or compared to one or more additional test agents. In an additional or alternative embodiment the methods comprises the further step of: (h) identifying the allergenic and / or sensitizing effect of the test agent. For example, step (h) may identify the test agent as being an allergen or a non-allergen and / or as a sensitizer or a non-sensitizer. Alternatively or additionally, step (h) may identify the relative allergenicity or allergenic potency and / or sensitizing effect or sensitizing potency of the test agent compared to a positive control and / or one or more additional test agents. The identification may be performed using any suitable statistical method or machine learning algorithm known in the art, such as Random Forest (RF), Support Vector Machine (SVM), Principal Component Analysis (PCA), ordinary least squares (OLS), partial least squares regression (PLS), orthogonal partial least squares regression (O-PLS) and other multivariate statistical analyses (e.g., backward stepwise logistic regression model). For a review of multivariate statistical analysis see, for example, Schervish, Mark J. (November 1987). "A Review of Multivariate Analysis". Statistical Science 2 (4): 396–413. Preferably, Support Vector Machine (SVM) is used. Typically, allergenic or sensitizing agents are identified using a support vector machine (SVM), (e.g. e1071 1.5-24). However, any other suitable means may also be used. SVMs may also be used to determine the ROC AUCs of biomarker signatures comprising or consisting of one or more biomarkers as defined herein. Support vector machines (SVMs) are a set of related supervised learning methods used for classification and regression. Given a set of training examples, each marked as belonging to one of two categories, an SVM training algorithm builds a model that predicts whether a new example falls into one category or the other. Intuitively, an SVM model is a representation of the examples as points in space, mapped so that the examples of the separate categories are divided by a clear gap that is as wide as possible. New examples are then mapped into that same space and predicted to belong to a category based on which side of the gap they fall on. More formally, a support vector machine constructs a hyperplane or set of hyperplanes in a high or infinite dimensional space, which can be used for classification, regression or other tasks. Intuitively, a good separation is achieved by the hyperplane that has the largest distance to the nearest training datapoints of any class (so-called functional margin), since in general the larger the margin the lower the generalization error of the classifier. For more information on SVMs, see for example, Burges, 1998, Data Mining and Knowledge Discovery, 2:121–167. In one embodiment of the invention, the SVM is 'trained' prior to performing the methods of the invention using biomarker profiles of known agents (namely, known allergenic / sensitizer or non-allergenic / non-sensitizer agents). By running such training samples, the SVM is able to learn what biomarker profiles are associated with agents capable of inducing allergy and / or sensitization. Once the training process is complete, the SVM is then able to predict whether or not the biomarker sample tested is from an allergenic or non-allergenic / sensitizing or non-sensitizing agent. Decision values for individual SVMs can be determined by the skilled person on a case- by-case basis. In one embodiment, the test agent is classified as allergenic and / or a sensitizer if one or more test (or replicate thereof) have an SVM decision value of >0. In one embodiment, the test agent is classified as non-allergenic and / or a non-sensitizer if one or more test (or replicate thereof) have an SVM decision value of ≤0. This allows test agents to be classified as allergenic or non-allergenic / sensitizing or non-sensitizing. However, this training procedure can be by-passed by pre-programming the SVM with the necessary training parameters. For example, allergenic and / or sensitizing agents can be identified according to the known SVM parameters using the SVM algorithm described in WO 2012 / 056236, WO 2013 / 160882, or WO 2016 / 083604, based on the measurement of all the biomarkers listed in one or more of Tables A-E. It will be appreciated by skilled persons that suitable SVM parameters can be determined for any combination of the biomarkers listed in Tables A-E by training an SVM machine with the appropriate selection of data (i.e. biomarker measurements from cells exposed to known allergenic and / or non-allergenic agents or sensitizing and / or non-sensitizing agents). Alternatively, the Table A-E biomarkers may be used to identify allergenic proteins and / or sensitizing agents according to any other suitable statistical method known in the art. Alternatively, the Table A-E data may be used to identify agents capable of inducing allergy and / or sensitization according to any other suitable statistical method known in the art (e.g., ANOVA, ANCOVA, MANOVA, MANCOVA, Multivariate regression analysis, Principal components analysis (PCA), Factor analysis, Canonical correlation analysis, Canonical correlation analysis, Redundancy analysis Correspondence analysis (CA; reciprocal averaging), Multidimensional scaling, Discriminant analysis, Linear discriminant analysis (LDA), Clustering systems, Recursive partitioning and Artificial neural networks). Preferably the methods of the invention are performed in vitro. In an additional or alternative embodiment steps (b), (c), (e) and / or (g) of the methods of the invention comprise or consist of measuring the expression of two or more biomarkers listed in Tables A, B, C, D or E, for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, or 391 of the biomarkers listed in Tables A, B, C, D or E. For example, steps (b), (c), (e) and / or (g) may comprise or consist of measuring the expression of all of the biomarkers listed in Tables A, B, C, D or E. By "expression" we mean the presence, level and / or amount of the biomarker. By "biomarker" we include any biological molecule, or component or fragment thereof, the measurement of which can provide information useful in determining the sensitizing effect and / or the allergenicity of a test agent. Thus, in the context of Tables A, B, C, D, and E, the biomarker may be a nucleic acid molecule, such as a mRNA or cDNA. Alternatively, the biomarker may be a protein encoded by the nucleic acid molecule or carbohydrate moiety, or an antigenic component or fragment thereof. In an additional or alternative embodiment of the method of the seventh aspect the test agent is already known to be, or suspected of being, capable of inducing sensitization of the skin. For example, the test agent may already be known to be capable of inducing sensitization of the skin by using a method already known in the art, for instance a method described WO 2012 / 056236 and / or Johansson H et al. The GARD assay for assessment of chemical skin sensitizers. Toxicology in vitro 2013. In an alternative or additional embodiment, the method is for identifying skin sensitizer potency and skin sensitizer / non- sensitizer status of the test agent (i.e., identifying whether the test agent is a sensitizer or not and identifying its potency as a skin sensitizer). In an alternative or additional embodiment, the method comprises identifying whether the test agent is a sensitizer using the method described in WO 2012 / 056236 and / or Johansson H et al. By "skin sensitizing potency" we include or mean the strength of the skin sensitizing ability of an agent. For example, the relative potency or strength of sensitizing ability of an agent might lead to the ordering of a group of test agents from most potent to least potent or vice versa, and / or it might lead to their categorization according to one or more known regulation or system. By "sensitization status" we include or mean whether or not a chemical entity (or mixture of chemical entities) is a sensitizer or not (e.g., a skin sensitizer and / or a respiratory sensitizer). By "skin sensitizing" we mean any agent capable of inducing and triggering a Type IV delayed-type hypersensitivity reaction in a mammal. Preferably, the Type IV delayed-type hypersensitivity reaction is DC-mediated. In an additional or alternative embodiment the skin sensitization potency determined by the method is categorised according to the European Classification, Labelling and Packaging (CLP) Regulation (EC) 1272 / 2008. This system is based on the United Nations' Globally Harmonised System (GHS) and from June 2015, the only legislation to apply to the classification and labelling of both substances and mixtures. It requires companies to classify, label and package their products appropriately before placing them on the market. It provides the categories: 1A (strong), 1B (weak), or no cat (no sensitizer). For example, the method may provide: (i) one or more agent of potency category 1A; (ii) one or more agent of potency category 1B; and / or (iii) one or more agent of potency category no category In an additional or alternative embodiment the skin sensitization potency determined by the method is categorised according to the system described in Basketter et al., 2014, 'Categorization of chemicals according to their relative human skin sensitizing potency,' Dermatitis, 25(1):11-21, i.e. categories 1 (strongest sensitizer), 2, 3, 4, 5, or 6 (true non- sensitizer) (e.g. Table 4, Figure 4). For example, the method may provide: (i) one or more agent of potency category 1; (ii) one or more agent of potency category 2; (iii) one or more agent of potency category 3; (iv) one or more agent of potency category 4; (v) one or more agent of potency category 5; and / or (vi) one or more agent of potency category 6 (e.g., see present Table 8 and / or Basketter et al., 2014 supra.). In an additional or alternative embodiment skin sensitization potency is categorised according to the local lymph node assay (LLNA) classification, Guinea pig maximisation test (GPMT) or no observed-effect level (NOEL). For a detailed description of LLNA see Basketter, D.A., et al., Local lymph node assay - validation, conduct and use in practice. Food Chem Toxicol, 2002. 40(5): p. 593-8. For a detailed description of the guinea pig maximization test see Magnusson, B. and A.M. Kligman, The identification of contact allergens by animal assay. The guinea pig maximization test. J Invest Dermatol, 1969. 52(3): p. 268-76. For a detailed description of the no observed-effects level (NOEL) test in relation to skin sensitizer potency see Basketter et al., 2005, 'Evaluation of the skin sensitizing potency of chemicals by using the existing methods and considerations of relevance for elicitation' Contact Dermatitis, 52(1):39-43; and Griem, P., et al., 2003, 'Proposal for a risk assessment methodology for skin sensitization based on sensitization potency data.' Regul. Toxicol. Pharmacol., 38:269-290. For a correlation between NOEL and potency levels, see also WHO Library Cataloguing-in-Publication Data. Skin sensitization in chemical risk assessment. (IPCS harmonization project document: no. 5), ISBN 978 92 4 156360 4 (in particular, Table 1 on pages 26-28). In an additional or alternative embodiment the expression of one or more biomarkers measured in step (c) is measured in the cells provided in step (a) prior to and following exposure to the skin sensitizing agent of predetermined potency, and wherein the difference in expression between the one or more biomarkers prior to and following exposure to the test agent is indicative of the potency of the skin sensitizing agent of step (b). In an additional or alternative embodiment the expression of one or more biomarkers measured in step (c) is measured in the cells provided in step (a) prior to and following exposure to the skin sensitizing agent of predetermined potency, and wherein the difference in expression between the one or more biomarkers prior to and following step (c) is indicative of the potency of the skin sensitizing agent of step (b). By 'difference in expression' we include that the presence and or amount in a first sample (e.g., a test agent sample) differs from that of a second sample (e.g., a control agent sample). Preferably the presence and / or amount is no more than 40% of that of the comparison sample, for example, no more than 39%, 38%, 37%, 36%, 35%, 34%, 33%, 32%, 31%, 30%, 29%, 28%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or 0%. In an additional or alternative embodiment the one or more biomarker is measured in the cells provided in step (a) prior to and following exposure to the test agent, and wherein the difference in expression between the one or more biomarkers prior to and following exposure to the test agent is indicative of the skin sensitizing potency of the test agent of step (b). Hence, the cells provided in step (a) may provide both the negative control and the test result. In an additional or alternative embodiment the one or more biomarker is measured in the cells provided in step (a) prior to and following exposure to the test agent, and wherein the difference in expression between the one or more biomarkers prior to and following step (c) is indicative of the skin sensitizing potency of the test agent of step (b). Hence, the cells provided in step (a) may provide both the negative control and the test result. In an additional or alternative embodiment the method comprises the further steps of: (i) providing a further population of dendritic-like cells according to the first or second aspect; (j) exposing the cells provided in step (i) to a skin sensitizing agent of predetermined potency; (k) measuring in the cells of step (j) the expression of the one or more biomarkers measured in step (c); wherein the correspondence in expression between the one or more biomarkers measured in step (c) and the one or more biomarkers measured in step (k) is indicative of the skin sensitizing potency of the test agent. By 'correspondence in expression' we include that that the presence and or amount in a first sample (e.g., a test agent sample) is similar or identical to the presence and / or amount in a second sample (e.g., a control sample). Preferably the presence and / or amount is at least 60% of that of the control sample, for example, at least 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%. In an additional or alternative embodiment the method comprises the further step of: (l) identifying the skin sensitizing potency of the test agent. In an additional or alternative embodiment the skin sensitizing agent of predetermined potency comprises or consist of agents selected from the group consisting of 1-Butanol, 4-Aminobenzoic acid, Benzaldehyde, Chlorobenzene, Diethyl phthalate, Dimethyl formamide, Ethyl vanillin, Glycerol, Isopropanol, Lactic acid, Methyl salicylate, Octanoic acid, Propylene glycol, Phenol, p-hydroxybenzoic acid, Potassium permanganate, Salicylic acid, Sodium dodecyl sulphate, Tween 80, Zinc sulphate, 2,4- Dinitrochlorobenzene, Oxazolone, Potassium dichromate, Kathon CG (MC / MCI), Formaldehyde, 2-Aminophenol, 2-nitro-1,4-Phenylendiamine, p-Phenylendiamine, Hexylcinnamic aldehyde, 2-Hydroxyethyl acrylate, 2-Mercaptobenzothiazole, Glyoxal, Cinnamaldehyde, Isoeugenol, Ethylendiamine, Resorcinol, Cinnamic alcohol, Eugenol, Penicillin G, Geraniol and DMSO. In a preferred embodiment of the method of any aspect of the invention, step (b), (c), (e), (g) and / or (k) comprises or consists of measuring the expression of a nucleic acid molecule of one or more of the biomarkers. The nucleic acid molecule may be a DNA molecule or a cDNA molecule or an mRNA molecule. Preferably, the nucleic acid molecule is an mRNA molecule. However, the nucleic acid molecule may be a cDNA molecule. In one embodiment the measurement of the expression of one or more of the biomarkers in step (b), (c), (e), (g) and / or (k) is performed using a method selected from the group consisting of Southern hybridisation, Northern hybridisation, polymerase chain reaction (PCR), reverse transcriptase PCR (RT-PCR), quantitative real-time PCR (qRT-PCR), nanoarray, microarray, macroarray, autoradiography and in situ hybridisation. Preferably, the expression of one or more biomarker(s) is measured using a DNA microarray. In an additional or alternative embodiment the one or more biomarkers measured in step (b), (c), (e), (g) and / or (k) is measured using an array (e.g., a DNA array). In an additional or alternative embodiment the one or more biomarkers measured in step (b), (c), (e), (g) and / or (k) is measured using a whole genome array (e.g., the Affymetrix Human Gene 1.0 ST array or Affymetrix Human Gene 2.0 ST array). In an alternative or additional embodiment, the Nanostring nCounter system is used (e.g., custom Nanostring nCounter code sets based on selection from a whole genome array (e.g., Affymetrix Human Gene 1.0 ST array or Affymetrix Human Gene 2.0 ST array). The method may comprise measuring the expression of one or more biomarkers in step (b), (c), (e), (g) and / or (k) using one or more binding moieties, each capable of binding selectively to a nucleic acid molecule encoding one of the biomarkers identified in one or more of Tables A, B, C, D, E. Preferably, the method comprises measuring the expression of two or more biomarkers in step (b), (c), (e), (g) and / or (k) using two or more binding moieties, each capable of binding selectively to a nucleic acid molecule encoding one of the biomarkers identified in one or more of Tables A, B, C, D, E. For example, the expression of any particular combination of biomarkers described above may be measured using an equivalent combination of binding moieties capable of binding selectively to each of those biomarkers. In one embodiment the one or more binding moieties each comprise or consist of a nucleic acid molecule. In a further embodiment the one or more binding moieties each comprise or consist of DNA, RNA, PNA, LNA, GNA, TNA or PMO. Preferably, the one or more binding moieties each comprise or consist of DNA. In one embodiment, the one or more binding moieties are 5 to 100 nucleotides in length. However, in an alternative embodiment, they are 15 to 35 nucleotides in length. The one or more binding moieties may comprise or consist of one or more probe from the Human Gene 1.0 ST Array (Affymetrix, Santa Clara, CA, USA). Probe identification numbers are provided in Tables A-E herein. Suitable binding agents (also referred to as binding molecules or binding moieties) may be selected or screened from a library based on their ability to bind a given nucleic acid, protein or amino acid motif, as discussed below. In a preferred embodiment, the binding moiety comprises a detectable moiety. By a "detectable moiety" we include a moiety which permits its presence and / or relative amount and / or location (for example, the location on an array) to be determined, either directly or indirectly. Suitable detectable moieties are well known in the art. For example, the detectable moiety may be a fluorescent and / or luminescent and / or chemiluminescent moiety which, when exposed to specific conditions, may be detected. Such a fluorescent moiety may need to be exposed to radiation (i.e. light) at a specific wavelength and intensity to cause excitation of the fluorescent moiety, thereby enabling it to emit detectable fluorescence at a specific wavelength that may be detected. Alternatively, the detectable moiety may be an enzyme which is capable of converting a (preferably undetectable) substrate into a detectable product that can be visualised and / or detected. Examples of suitable enzymes are discussed in more detail below in relation to, for example, ELISA assays. The detectable moiety may be a radioactive moiety and comprise or consists of a radioactive atom. The radioactive atom may be selected from the group consisting of technetium-99m, iodine-123, iodine-125, iodine-131, indium-111, fluorine-19, carbon-13, nitrogen-15, oxygen-17, phosphorus-32, sulphur-35, deuterium, tritium, rhenium-186, rhenium-188 and yttrium-90. Hence, the detectable moiety may be selected from the group consisting of: a fluorescent moiety; a luminescent moiety; a chemiluminescent moiety; a radioactive moiety (for example, a radioactive atom); or an enzymatic moiety. Clearly, the agent to be detected (such as, for example, the one or more biomarkers in the test sample and / or control sample described herein and / or an antibody molecule for use in detecting a selected protein) must have sufficient of the appropriate atomic isotopes in order for the detectable moiety to be readily detectable. In an alternative preferred embodiment, the detectable moiety of the binding moiety is a fluorescent moiety. The radio- or other labels may be incorporated into the biomarkers present in the samples of the methods of the invention and / or the binding moieties of the invention in known ways. For example, if the binding agent is a polypeptide it may be biosynthesised or may be synthesised by chemical amino acid synthesis using suitable amino acid precursors involving, for example, fluorine-19 in place of hydrogen. Labels such as <com:Sup>99m< / com:Sup>Tc, <com:Sup>123< / com:Sup>I, <com:Sup>186< / com:Sup>Rh, <com:Sup>188< / com:Sup>Rh and <com:Sup>111< / com:Sup>In can, for example, be attached via cysteine residues in the binding moiety. Yttrium-90 can be attached via a lysine residue. The IODOGEN method (Fraker et al. (1978) Biochem. Biophys. Res. Comm. 80, 49-57) can be used to incorporate 1231. Reference ("Monoclonal Antibodies in Immunoscintigraphy", J-F Chatal, CRC Press, 1989) describes other methods in detail. Methods for conjugating other detectable moieties (such as enzymatic, fluorescent, luminescent, chemiluminescent or radioactive moieties) to proteins are well known in the art. It will be appreciated by persons skilled in the art that biomarkers in the sample(s) to be tested may be labelled with a moiety which indirectly assists with determining the presence, amount and / or location of said proteins. Thus, the moiety may constitute one component of a multicomponent detectable moiety. For example, the biomarkers in the sample(s) to be tested may be labelled with biotin, which allows their subsequent detection using streptavidin fused or otherwise joined to a detectable label. The method provided in the first aspect of the present invention may comprise or consist of, in step (b), (c), (e), (g) and / or (k), determining the expression of the protein of one or more biomarker defined in one or more of Tables A-E. The method may comprise measuring the expression of one or more biomarkers in step (b), (c), (e), (g) and / or (k) using one or more binding moieties each capable of binding selectively to one of the biomarkers identified in one or more of Tables A-E. The one or more binding moieties may comprise or consist of an antibody or an antigen-binding fragment thereof such as a monoclonal antibody or fragment thereof. The term "antibody" includes any synthetic antibodies, recombinant antibodies or antibody hybrids, such as but not limited to, a single-chain antibody molecule produced by phage- display of immunoglobulin light and / or heavy chain variable and / or constant regions, or other immunointeractive molecules capable of binding to an antigen in an immunoassay format that is known to those skilled in the art. We also include the use of antibody-like binding agents, such as affibodies and aptamers. The one or more protein-binding moieties may comprise a detectable moiety. The detectable moiety may be selected from the group consisting of a fluorescent moiety, a luminescent moiety, a chemiluminescent moiety, a radioactive moiety and an enzymatic moiety. In a further embodiment of the methods of the invention, step (b), (c), (e), (g) and / or (k) may be performed using an assay comprising a second binding agent capable of binding to the one or more proteins, the second binding agent also comprising a detectable moiety. Suitable second binding agents are described in detail above in relation to the first binding agents. Thus, the proteins of interest in the sample to be tested may first be isolated and / or immobilised using the first binding agent, after which the presence and / or relative amount of said biomarkers may be determined using a second binding agent. In one embodiment, the second binding agent is an antibody or antigen-binding fragment thereof; typically a recombinant antibody or fragment thereof. Conveniently, the antibody or fragment thereof is selected from the group consisting of: scFv; Fab; a binding domain of an immunoglobulin molecule. Alternatively, the second binding agent may be an antibody-like binding agent, such as an affibody or aptamer. Alternatively, where the detectable moiety on the protein in the sample to be tested comprises or consists of a member of a specific binding pair (e.g. biotin), the second binding agent may comprise or consist of the complimentary member of the specific binding pair (e.g. streptavidin). Where a detection assay is used, it is preferred that the detectable moiety is selected from the group consisting of: a fluorescent moiety; a luminescent moiety; a chemiluminescent moiety; a radioactive moiety; an enzymatic moiety. Examples of suitable detectable moieties for use in the methods of the invention are described above. Preferred assays for detecting serum or plasma proteins include enzyme linked immunosorbent assays (ELISA), radioimmunoassay (RIA), immunoradiometric assays (IRMA) and immunoenzymatic assays (IEMA), including sandwich assays using monoclonal and / or polyclonal antibodies. Exemplary sandwich assays are described by David et al in US Patent Nos. 4,376,110 and 4,486,530. Antibody staining of cells on slides may be used in methods well known in cytology laboratory diagnostic tests, as well known to those skilled in the art. Thus, in one embodiment the assay is an ELISA (Enzyme Linked Immunosorbent Assay) which typically involves the use of enzymes which give a coloured reaction product, usually in solid phase assays. Enzymes such as horseradish peroxidase and phosphatase have been widely employed. A way of amplifying the phosphatase reaction is to use NADP as a substrate to generate NAD which now acts as a coenzyme for a second enzyme system. Pyrophosphatase from Escherichia coli provides a good conjugate because the enzyme is not present in tissues, is stable and gives a good reaction colour. Chemiluminescent systems based on enzymes such as luciferase can also be used. Conjugation with the vitamin biotin is frequently used since this can readily be detected by its reaction with enzyme-linked avidin or streptavidin to which it binds with great specificity and affinity. In an alternative embodiment, the assay used for protein detection is conveniently a fluorometric assay. Thus, the detectable moiety of the second binding agent may be a fluorescent moiety, such as an Alexa fluorophore (for example Alexa-647). Preferably, steps (b) (c), (e), (g) and / or (k) of the methods are performed using an array. The array may be a bead-based array or a surface-based array. The array may be selected from the group consisting of: macroarray; microarray; nanoarray. Arrays per se are well known in the art. Typically they are formed of a linear or two- dimensional structure having spaced apart (i.e. discrete) regions ("spots"), each having a finite area, formed on the surface of a solid support. An array can also be a bead structure where each bead can be identified by a molecular code or colour code or identified in a continuous flow. Analysis can also be performed sequentially where the sample is passed over a series of spots each adsorbing the class of molecules from the solution. The solid support is typically glass or a polymer, the most commonly used polymers being cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene. The solid supports may be in the form of tubes, beads, discs, silicon chips, microplates, polyvinylidene difluoride (PVDF) membrane, nitrocellulose membrane, nylon membrane, other porous membrane, non-porous membrane (e.g. plastic, polymer, perspex, silicon, amongst others), a plurality of polymeric pins, or a plurality of microtitre wells, or any other surface suitable for immobilising proteins, polynucleotides and other suitable molecules and / or conducting an immunoassay. The binding processes are well known in the art and generally consist of cross-linking covalently binding or physically adsorbing a protein molecule, polynucleotide or the like to the solid support. Alternatively, affinity coupling of the probes via affinity-tags or similar constructs may be employed. By using well-known techniques, such as contact or non-contact printing, masking or photolithography, the location of each spot can be defined. For reviews see Jenkins, R.E., Pennington, S.R. (2001, Proteomics, 2,13-29) and Lal et al (2002, Drug Discov Today 15;7(18 Suppl):S143- 9). Typically the array is a microarray. By "microarray" we include the meaning of an array of regions having a density of discrete regions of at least about 100 / cm<com:Sup>2< / com:Sup>, and preferably at least about 1000 / cm<com:Sup>2< / com:Sup>. The regions in a microarray have typical dimensions, e.g. diameter, in the range of between about 10-250 μm, and are separated from other regions in the array by about the same distance. The array may alternatively be a macroarray or a nanoarray. Once suitable binding molecules (discussed above) have been identified and isolated, the skilled person can manufacture an array using methods well known in the art of molecular biology. In an additional or alternative embodiment one or more biomarker measured in step (b), (c), (e), (g) and / or (k) is a nucleic acid (e.g., DNA, mRNA or cDNA etc). In an additional or alternative embodiment one or more biomarkers measured in step (b), (c), (e), (g) and / or (k) is a protein or polypeptide. In an additional or alternative embodiment the method is performed in vitro, in vivo, ex vivo or in silico. Preferably, the method is performed in vitro. In an additional or alternative embodiment, the method comprises one or more of the following steps: (i) cultivating dendritic-like cells according to the first or second aspect; (ii) seeding cells of (i) in one or more wells, preferably at steady state growth phase, e.g. wells of one or more multi-well assay plate; (iii) adding to one or more well(s) of (ii) the agent(s) to be tested; (iv) adding to one or more separate well(s) of (ii) positive control(s); (v) adding to one or more separate well(s) of (ii) negative control(s); and / or leaving one or more separate well(s) of (ii) unstimulated to obtain a medium control; (vi) incubating cells in wells of (iii)-(v), preferably for about 24 hours; and, optionally, harvesting cells from wells of (iii)-(v); and, further optionally, removing supernatant and storing in TRIzol reagent; (vii) isolating purified total RNA from the cells of (vi) and, optionally, converting mRNA into cDNA; (viii) quantifying expression levels of individual mRNA transcripts from (vii), e.g. using an array, such as an Affymetrix Human Gene 1.0 ST array; (ix) exporting and normalizing data from (viii), e.g. using appropriate algorithms; (x) isolating data from (ix) originating from biomarkers of one or more of Tables A-E); (xi) applying a prediction model to the data of (x), e.g. a frozen SVM model previously established and trained on historical data to predict the allergenicity or sensitizer status (e.g. classify as allergen / non-allergen and / or sensitizer / non-sensitizer), of tested agents(s) and negative / positive control(s). By "test protein" we include any protein or proteinaceous entity (or mixture of proteins or proteinaceous entities) for which allergenic or sensitization status is to be determined. By "allergenic" we include or mean a protein (or mixture of proteins) which is an allergen, and / or which is capable of inducing an allergic response, in a mammal. In an additional or alternative embodiment the allergenicity comprises a hypersensitivity response (e.g., a cell-mediated hypersensitivity response). In an additional or alternative embodiment the hypersensitivity response is a type I hypersensitivity response. In an additional or alternative embodiment the hypersensitivity response is respiratory allergy. In an additional or alternative embodiment, the method of the eighth aspect is for identifying the sensitization status of a protein in a mammal. For example, the expression of the one or more biomarkers measured in step (b) or (c) may be indicative of the sensitization status of the test protein. By "sensitization status" we include or mean whether or not a test protein (or mixture of test proteins) is a sensitizer or not (e.g., a skin sensitizer and / or a respiratory sensitizer). In an additional or alternative embodiment, the method is for identifying proteins which are capable of inducing respiratory sensitization in a mammal. For example, the expression of the two or more biomarkers measured in step (c) may be indicative of the respiratory sensitizing effect of the test protein. In one embodiment, the method is for identifying proteins capable of inducing a respiratory hypersensitivity response. Preferably, the hypersensitivity response is a humoral hypersensitivity response, for example, a type I hypersensitivity response. In one embodiment, the method is for identifying agents capable of inducing respiratory allergy. By "indicative of the respiratory sensitizing effect of the test protein" we include determining whether or not the test protein is a respiratory sensitizer and / or determining the potency of the test protein as a respiratory sensitizer. By proteins "capable of inducing respiratory sensitization" we mean any protein capable of inducing and triggering a Type I immediate hypersensitivity reaction in the respiratory tract of a mammal. Preferably the mammal is a human. Preferably, the Type I immediate hypersensitivity reaction is DC-mediated and / or involves the differentiation of T cells into Th2 cells. Preferably the Type I immediate hypersensitivity reaction results in humoral immunity and / or respiratory allergy. The conducting zone of the mammalian lung contains the trachea, the bronchi, the bronchioles, and the terminal bronchioles. The respiratory zone contains the respiratory bronchioles, the alveolar ducts, and the alveoli. The conducting zone is made up of airways, has no gas exchange with the blood, and is reinforced with cartilage in order to hold open the airways. The conducting zone humidifies inhaled air and warms it to 37°C (99°F). It also cleanses the air by removing particles via cilia located on the walls of all the passageways. The respiratory zone is the site of gas exchange with blood. In one embodiment, the protein "capable of inducing respiratory sensitization" is a protein capable of inducing and triggering a Type I immediate hypersensitivity reaction at a site of lung epithelium in a mammal. Preferably, the site of lung epithelium is in the respiratory zone of the lung, but may alternatively or additionally be in the conductive zone of the lung. In an additional or alternative embodiment, the method is for identifying food proteins which are allergenic in a mammal. For example, the expression of the two or more biomarkers measured in step (c) may be indicative of the allergenicity of the food protein. Preferably, the allergenicity of the food protein is due to a Type 1 hypersensitivity response. The mammal may be any domestic or farm animal. Preferably, the mammal is a rat, mouse, guinea pig, cat, dog, horse or a primate. Most preferably, the mammal is human. In a further aspect of the invention there is provided the use of a population of dendritic- like cells according to the first or second aspect for determining the sensitizing effect and / or the allergenicity of a test agent. In a further aspect of the invention there is provided an analytical kit comprising: i. an array comprising one or more binding moieties; and ii. one or more cell or a cell culture as defined in the first or second aspect; and iii. (optionally) one or more control agent; and ίV. (optionally) instructions for use. In a further aspect of the invention there is provided an analytical kit for use in a method of the invention comprising: i. an array comprising one or more binding moieties as defined herein; and ii. one or more cell or a cell culture as defined in the first or second aspects; and iii. (optionally) one or more control agent; and iv. (optionally) instructions for performing the method of the invention. The skilled person will appreciate that all non-conflicting embodiments may be used in combination. Hence, embodiments from one aspect of the invention may equally be applied to another aspect of the invention. The listing or discussion of an apparently prior-published document in the specification should not necessarily be taken as an acknowledgment that the document is part of the state of the art or common general knowledge. Preferred, non-limiting examples which embody certain aspects of the invention will now be described, with reference to the following figures: Figure 1. The expression levels for the different surface markers were used in a hierarchical clustering to compare the cell lines. The numbers in the label represents the experiments. The clustering groups the cells in two separate clusters. Figure 2. SenzaCell; Distribution of the biological processes that were associated with the genes predicted to be affected with high or moderate impact by the unique variants. Figure 3. MUTZ-3; Distribution of the biological processes that were associated with the genes predicted to be affected with high or moderate impact by the identified variants. Figure 4. A) A hierarchical clustering of the RNA-seq data shows a separate cluster for the samples obtained at experiment 3. The cells from experiment 1 and 2 form separate clusters for the cell lines. B) The PCA plot of the samples show that the largest source of variation can be explained by differences between the cell lines. It is also clear that the samples prepared at experiment 3 deviates from the remaining samples. Figure 5. The pie chart represents the distribution of the molecular functions that the discovered Differentially Expressed Genes (DEGs) were mapped to using PANTHER. Figure 6. SVM skin sensitizer predictions when using the expression values obtained from MUTZ-3 and SenzaCell after being stimulated with the test chemicals DNCB and 2- hydroxyethylacrylate. All the predictions correctly correspond to the true class. EXAMPLE 1 Background Allergic contact dermatitis (ACD) is an inflammatory skin disease that affects a large proportion of the population. It is caused by the repeated exposure to skin sensitizers and results in symptoms such as eczema. The sensitization phase of ACD requires a skin sensitizer to activate an immune response leading to the production of allergen specific effector and memory T-cells (1). The known mechanisms for sensitization have been well described (1-4). In short, skin sensitizers gain access to the viable dermis where it reacts with proteins to form hapten-protein complexes. These hapten-protein complexes can be recognized by different immune cells or structural cells that exert inflammatory signals. Activated dendritic cells process the hapten-protein complexes and migrate to lymph nodes where they present them to naïve T-cells on MHC-molecules. Subsequently, effector and memory T-cells are produced that upon renewed exposure to the same sensitizer elicits inflammatory functions, giving rise to the symptoms of ACD (3). Conventional methods for assessing chemicals' abilities to induce allergic reactions at skin contact have mainly been conducted using animal models (1). Legislations and trends drive research to come up with better and more ethical in-vitro methods for the evaluation of chemical sensitizers (5-7). The Genomic Allergen Rapid Detection (GARD) is an in vitro assay developed at Department of Immunotechnology, Lund University, for the assessment of chemical sensitizers. It uses transcriptional profiles from a dendritic cell-like cell line (8), to predict the sensitizing potential of chemicals (9). The transcriptional profiles consist of genes that were identified as having the greatest predicting performance in distinguishing sensitizers from non-sensitizers. The genes were identified using statistical data mining methods on transcription data originating from Affymetrix microarrays. No a priori information of the genes in the GARD Prediciton Signature (GPS) were used for their identification, which could have made the signature specific for the cell line (10). The inventors now provide a non-naturally occurring dendritic-like myeloid leukemia cell line "SenzaCell" (ATCC Patent Deposit Designation PTA-123875; deposited at ATCC on 9 March 2017) which is suitable for use in the GARD assays. SenzaCell has been compared to the MUTZ-3 dendritic-like cell line which may also be used in GARD methods. The comparison included a phenotypic analysis where the expression of a panel of biomarkers were compared, a transcriptional analysis where the transcription levels of the cell lines were compared, a comparison of their DNA sequences and a functional analysis, which revealed many quantifiable differences in the phenotype and transcriptional profiles. Materials and Methods Cell maintenance MUTZ-3 (DSMZ, Braunschweig, Germany (www.dsmz.de; DSMZ No. ACC 295)) and SenzaCell cells were cultivated in minimum essential medium alpha (α-MEM) (GE Healthcare Life Sciences, Logan, UT) supplemented with 20% (V / V) fetal calf serum (FCS) (Thermo Fisher Scientific, Waltham, MA) and 40 ng / ml granulocyte macrophage colony stimulating factor (GM-CSF) (Miltenyi Biotec, Bergisch Gladbach, Germany). Throughout this report the media is referred to as complete media. Cells were maintained at a concentration of 200 000 cells / ml and the media was renewed every 3-4 days. The cells were maintained at 37°C and 5% CO<com:Sub>2< / com:Sub>. Phenotypic characterization Growing cells were harvested, counted and seeded at a concentration of 200 000 cells / ml in complete media. To prepare the cells for staining, 1 ml of cell suspension was transferred to FACS tubes. The cells were washed in wash buffer, PBS (GE Healthcare Life Sciences) with 1% BSA (Saveen & Werner, Limhamn, Sweden) (w / V), twice. All washing steps were performed by the addition of 1 ml of wash buffer, centrifugation at 1200 rpm at 4°C and removal of the supernatant. After the second wash, the cells were resuspended in 50 µl wash buffer. The antibodies; isotype PE / FITC, CD40 FITC, CD54 PE, CD86 FITC (BD Pharmingen, San Diego, CA); CD1a FITC, CD5 FITC, CD14 PE, CD19 PE (DAKO); CD13 PE, CD123 PE, OX40L PE (Pharmingen, San Diego, CA); CD11b PE, CD34 FITC, CD32 FITC, CD80 PE, HLA-DR FITC, CD137 PE, CD16 PE, CD64 PE (BD, Franklin Lakes, NJ); BDCA-3 APC (Miltenyi, Bergisch Gladbach, Germany); CD209 PE(R&D Systems, Minneapolis, MN); BDCA-1 APC (eBioscience, San Diego, CA); OX40 PE (BD Bioscience, San Jose, CA); CD15 FITC (Milteny); TLR2 PE, TLR4 PE (biolegend, San Diego, CA), were added to the resuspended cells and incubated for 15 min at 4°C in the dark. Following staining, the cells were washed in wash buffer once more and then resuspended in 200 µl of wash buffer. The cells were kept in 4°C until analyzed with flow cytometry. The flow cytometry was performed on a FACS CANTO II (BD Bioscience) with BD DIVA software (BD Bioscience) as the data acquisition program where 10 000 events were recorded for each sample. The data was analyzed using FACS Express V3 (De Novo Software, Los Angeles, CA). Appropriate gates were set using isotype controls and unstained cells. The measurements were performed at three separate experiments with technical duplicates at each, generating 6 measurements for each marker and cell line. The expression levels were compared using t-tests where the generated p-values were corrected with the Benjamini Hochberg method to control the false discovery rate. A clustering algorithm was performed to compare the cell lines. The clustering was performed using R (15). A bootstrap algorithm was performed to assess the stability of the discovered clusters using the fpc (16) package. The bootstrap algorithm was run for 5000 iteration and the calculated mean Jaccard coefficients was used as an indication on cluster stability. DNA – Whole genome sequencing DNA from both MUTZ-3 and SenzaCell cells was isolated using Quick-gDNA™ Miniprep (Zymo Research, Irvine CA). The isolation was performed as follows; 5*10^6 cells were harvested and centrifuged and the supernatant was removed. The remaining cell pellets were lysed in Quick-gDNA<com:Sup>TM< / com:Sup> genomic lysis buffer and incubated for 10 minutes. The lysed cells were loaded to the supplied spin columns and washed. DNA was eluted in RNAse / DNase free water. DNA concentration and DNA purity were determined using NanoDrop, and the quality was evaluated by gel electrophoresis. The DNA whole genome sequencing was performed by SciLifeLabs (Stockholm, Sweden). The services from SciLifeLabs included library preparation, sequencing and best practice basic analysis. The DNA libraries were prepared with Illumina TruSeq PCR-free, 350 bp and the sequencing were performed with Illumina HiSeq X v2.5, PE 2x150 bp at 30X coverage. The best practice basic analysis included mapping of the reads to the human assembly build 37 using bwa –mem. The Genome Analysis Toolkit (GATK) workflow (17, 18) for best practice analysis were followed for variant calling and genomic variant call format (gVCF) files were delivered from SciLifeLabs. The obtained gVCF files were merged and genotyped using GATK genotypeGVCFS. The variant were further processed using GATK Variant Quality Score Recalibration (VQSR) as recommended by the GATK workflow. The VQSR calculates new variant quality scores and filters variants that are predicted to be false positive discoveries using machine learning. The recalibrated variant call format (VCF) file was annotated and the variant effects were predicted using snpEff (19) to the human assembly build GRCh37.75. The variants that were unique to either of the cell lines were identified using SnpSift (20) casecontrol and the other variants were filtered using SnpSift filter. The list of unique variants was further filtered by their genotype quality scores were variants with a score <20 was removed (21). Finally variants predicted to have a high or moderate impact were retained for further analysis. PANTHER classification system (22) was used for classification of the molecular function of the genes which were identified to be impacted by the variants. RNA – RNAseq Total RNA was isolated from both MUTZ-3 and SenzaCell cell lines in three experiments to generate triplicate RNAseq samples. 200,000 cells were isolated and lysed in TRIzol reagent (Thermo Scientific, Waltham, MA). RNA was isolated using Direct-zol<com:Sup>IM< / com:Sup> RNA Miniprep (Zymo research). The lysed samples were mixed with ethanol and added to the spin columns. The RNA was bound and washed with the supplied wash buffers. RNA was eluted in RNase / DNase free water and quality controlled with Agilent Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA). The samples were stored at -80°C until shipped on dry ice to SciLifeLabs for RNA-seq. The libraries were prepared using Illumina TruSeq stranded mRNA, Poly-A selection. The sequencing was performed using Illumina HiSeq Rapid mode v2, SR 1x50bp. The best practice basic analysis was performed by SciLifeLabs which included mapping of the reads using topHat v2.0.4 (23), sorting of the generated bam files with samtools (24), marking duplicates with piccard-tools and quantifying the counts using HTSeq (25). The obtained count table were loaded into R and differential expression analysis was performed using edgeR v3.14.0 (26) and DESeq2 v1.12.4 (27), which performs normalization and fitting of negative binomial models to the count data, enabling effective differential expression analysis. The recommended workflows for differential expression (DE) analysis were followed for both packages. The model matrix used for hypothesis testing were designed to incorporate the experiment batch in the model due to batch effects which were discovered when analyzing PCA plots of the samples. A transcript was considered differentially expressed if both edgeR and DESeq called it significantly differentially expressed with a false discovery rate below 0.05. The molecular functions and the biological processes that the identified transcripts were mapped to were analyzed using PANTHER classification system. To identify gene ontology (GO) terms that were over- or underrepresented among the differentially expressed transcripts an overrepresentation test was performed, also using PANTHER. The background reference list was submitted as all the non-zero counts that were obtained in the count table, which is the same list that was entered into the DE analysis. The p-values of the identified GO terms were corrected with the Bonferroni method. GO terms with a corrected p-value below 0.05 were considered significantly over- or underrepresented. Additionally, pathway analysis was performed using Signaling Pathway Impact Analysis v2.24.0 (SPIA) (28) and KEGG pathways (29, 30) release 79.0. The list of significant DE transcripts was entered with accompanying log<com:Sub>2< / com:Sub>-fold change values and all the non-zero transcripts were entered as background. The log<com:Sub>2< / com:Sub>-fold change values were calculated using DESeq2 v1.12.4. Finally a concordance analysis was made for the results of the phenotype analysis and the RNA-seq analysis. The genes corresponding to the measured surface markers were compared to the surface marker expression. The comparison was made similar to an evaluation of a classification with the classes significantly upregulated / expressed, significantly downregulated / expressed or no significant difference between the two cell lines. Therefore, if both the RNA-seq analysis and the phenotype analysis calls the transcript level or surface expression significantly higher, this would be considered a concordant result. Cohens Kappa (31) was calculated as an indication of the concordance between the analysis methods. Functional analysis MUTZ-3 was used in the GARD assay to assess its ability to distinguish skin sensitizers from non-sensitizers using the GARD prediction signature as compared to SenzaCell. The GARD standard operating procedures were followed which has previously been described in detail (9). In short, the cells (MUTZ-3 or SenzaCell) were seeded in 24-well plates at a volume of 1.8 ml and a cell concentration of 222 000 cells / ml. The chemicals used for the stimulation were (2, 4)-dinitrochlorobenzene (DNCB) and 2-hydroxyethylacrylate. An unstimulated sample was also included as a negative control. DNCB was dissolved in DMSO to a concentration of 4 mM and 2-hydroxyethylacrylate in water to a concentration of 100mM. Both chemicals were then diluted, in <com:Math><semantics>α<annotation encoding="application / x-tex">\alpha< / annotation>< / semantics>< / com:Math>-MEM supplemented with 20% FCS, 100X and finally diluted once more 10X as 200 µl was added to the wells. The in-well concentration for the stimulations was 4 µM and 100 µM for DNCB and 2- hydroxyethylacrylate, respectively. 200 µl of MEM-alpha was added to the unstimulated cells, giving an in-well cell concentration of 200 000 cells / ml for every sample. The cells were incubated with the chemicals for 24 h at 37°C at 5% CO<com:Sub>2< / com:Sub>. Following incubation, cells were harvested into RNase free Eppendorf tubes and lysed in TRIzol. Cell viability was assessed by flow cytometry using propidium iodide (PI) (Thermo Fisher Scientific) staining. RNA was extracted and purified using Direct-zol RNA kits (Zymo research). RNA was extracted as described and quality controlled using Agilent Bioanalyzer 2100Samples with an RNA integrity numbers (RIN) ≥8 and an RNA concentration ≥20 ng / µl was used for quantification. The genes in the GPS (see Table A below) were quantified using NanoString nCounter systems (NanoString Technologies, Seattle, WA), using protocols and reagents supplied by the manufacturer. The raw counts of the genes were exported from NanoString and normalized by a count per total counts normalization, where each gene's count is divided by the sum of counts for a single sample. The classification was performed by Support vector machine from the R package e1071 (32) with a training set consisting of gene profiles of 40 chemical stimulations in replicates (10). The data was aligned with the training data prior to the classification by calculating the shifts in the first 4 principal components for the unstimulated samples in both data sets. The calculated shifts were then used to adjust every sample from the test samples. Methodology for distinguishing skin sensitizers from non-sensitizers using the GARD prediction signature is also described in detail in WO 2012 / 056236; Johansson et al. (2017) Evaluation of the GARD assay in a blind Cosmetics Europe study. ALTEX Online first February 17, 2017; Forreryd et al. (2016) From genome-wide arrays to tailor-made biomarker readout – Progress towards routine analysis of skin sensitizing chemicals with GARD. Toxicolgy In Vitro; Johansson et al. (2014) GARD in-house validation – A proof of concept. Tox Sci; Johansson et al., (2011) A genomic biomarker signature can predict skin sensitizers using a cell-based in vitro alternative to animal tests. BMC Genomics, 2011). TABLE A [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] Table A legend. Genes were annotated, using the NetAffx database from Affymetrix (www.affymetrix.com, Santa Clara USA). When found, the Unigene (www.ncbi.nlm.nih.gov / UniGene / ) ID was chosen as the gene identifier. In the cases where no Unigene ID was reported the best alternative ID was given. Results Phenotype analysis To investigate any indications of phenotypic differences in SenzaCell compared to MUTZ- 3, the expression of a panel of surface markers, Table I, were measured in both cell lines. The selected surface markers are associated with dendritic cells, myeloid cells, hematopoietic cells or cell activation. The populations of positive cells were calculated and the population sizes were compared using t-tests. Out of the 26 surface markers that were measured, 12 were significantly differentially expressed between the cell lines when considering a false discovery rate < 0.05 significant, see rows shaded in Table I. The differentially expressed surface markers were CD1a, CD11b, CD14, CD34, CD15, CD32, CD40, CD54, HLA-DR, CD64, Toll like receptor (TLR) 4 and TLR-2. The expression of CD54 is however nearly identical in the cell lines and close to the highest obtainable value, and should be interpreted with caution. The expression was also considered as binary, + if the surface marker was detected and – otherwise. The binary expression of the surface markers were very similar between the cell lines. The only surface markers that showed a different binary expression was CD80 and possibly OX40L. A hierarchical clustering algorithm was performed to further compare the cell lines, see Figure 1. The clustering groups MUTZ-3 and SenzaCell in 2 separate clusters. A bootstrap algorithm with resampling was performed to evaluate the stability of the identified clusters. The mean Jaccard coefficients for SenzaCell and MUTZ-3 were determined to be 0.85 and 0.89 respectively, which is indicative of stable clusters. Table I. The expression of a panel of biomarkers were measured for both SenzaCell and MUTZ-3. The expression values are given as the mean percent positive cells ± the standard deviation. T-tests were performed to compare the means of the expression values. The p-values were corrected using Benjamini Hochberg correction. Rows shaded in green represent markers with a corrected p-value below 0.05. The calculations are based on 6 measurements in biological triplicates. A binary representation of the surface expression is represented as + if expressed or - if not expressed. The expression of the surface marker's corresponding genes are given, showing the cell line that exhibits the highest expression if significantly different. HLA-DR is not reported in the RNA expression column due to its complex genetics: [Image disponible dans le document PDF, Image available in the PDF document] Whole Genome Sequencing Whole genome sequencing was performed to identify indicators of genetic differences betweenSenzaCell and MUTZ-3. Indicators could be represented by variants only discovered in either of the cell lines. The investigated variants consisted of single nucleotide polymorphisms (SNPs), insertions or deletions. The number of raw variants that were discovered in the cell lines was 5,080,918 and 5,073,307 in SenzaCell and MUTZ-3 respectively. The gVCF files were merged and genotyped and the variant quality scores in the outputted VCF file were recalibrated. Variants with low quality scores were filtered and removed from further analysis. The similarity between the cell line genomes and the reference genome was calculated to 99.86% for both cell lines, resulting in a variant frequency of 1 variant per ~720 bp. Variants unique to either of the cell lines were identified by finding positions where one cell line had an identified variant and the other cell line were homozygous to the reference genome. Further filtering was performed to remove variants where the certainty of the homozygous calls was low, by filtering on the genotype quality scores. The obtained variant list consisted of 7,977 variants that could only be found in the SenzaCell and 5,672 variants unique to the MUTZ-3 cell line. Though the list of variants had been decreased significantly, further filtering was necessary to identify mutations that could have an impact on the cells. Variants were therefore filtered to remove low impact mutations. Mutations that were predicted to have a high or moderate impact in SenzaCell can be seen in Table 2 and the identified variants for MUTZ-3 can be seen in Table 3. 14 variants were discovered in SenzaCell that matched the described criteria and 28 were found in MUTZ-3. The predicted effects ranged from amino acid substitutions to more severe mutations such as gaining a new stop codons or changes in splice sites. The biological processes that the genes that were impacted by the variants could be mapped to were determined using PANTHER, see Figure 2 and Figure 3. Finally, a similar filtering strategy was performed to determine the number of common variants that could be identified in the cell lines, which resulted in the identification of 4,298,116 variants. Table 2. Unique variants that were only found in SenzaCell (S) which were predicted to have a high or moderate effect. Predicted effects were determined using snpEff. .Gene: identified gene to be affected by the variant, CHR: Chromosome where variant was called, POSITION: variant's position on the chromosome, IMPACT: predicted impact of variant, PREDICTED EFFECT: predicted impact by snpEff, X-GQ: Phred based quality score for genotype quality for respective cell line: [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] Table 3. Unique variants that were only found in MUTZ-3 (M) that were predicted to have a high or moderate effect. Predicted effects were determined using snpEff. .Gene: 5 identified gene to be affected by the variant, CHR: Chromosome where variant was called, POSITION: variant's position on chromosome, IMPACT: predicted impact of variant, PREDICTED EFFECT: predicted impact by snpEff, X-GQ: Phred based quality score for genotype quality for respective cell line: [Image disponible dans le document PDF, Image available in the PDF document] RNA-seq analysis The transcriptomes of the cell lines were compared to assess the cell states during normal growth and identify any differences between them. An initial analysis of the data was performed by creating a PCA plot of the samples and performing a hierarchical clustering analysis, Figure 4. The PCA plot indicated the presence of batch effects as the samples from experiment 3 exhibited deviating values in the 2<com:Sup>nd< / com:Sup> principal component compared to the samples from the first two experiments. The samples from experiment 3 also formed a separate cluster in the hierarchical clustering which further strengthens the observation that batch effects affected the data. The samples obtained from the first two experiments seemed more similar and samples from the same cell line formed separate groups and clusters. EdgeR and DESeq were used to search for differentially expressed transcripts between the cell lines, where the generalized linear models were designed to account for the observed batch effects. 3644 transcripts were identified as significantly differentially expressed (listed in Supplementary Table 1). The identified transcripts were mapped to molecular functions and biological processes using PANTHER (Figure 3). The majority of the transcripts were mapped to the molecular functions catalytic activity and binding and the biological processes cellular- and metabolic processes. An overrepresentation test was then performed to investigate if any biological processes were significantly under- or overrepresented among the DE transcripts. 94 GO terms were identified as statistically under- or overrepresented with a Bonferroni corrected p-value below 0.05, see Supplementary Table 2. To gain further insight into the differences between the cell lines a topological pathway analysis was also performed. The pathway analysis discovered 19 activated and 2 inhibited signaling pathways in MUTZ-3 compared to SenzaCell, Table 4. The regulation of the genes selected in the GPS are important for the identification and separation of sensitizers and non-sensitizers in the GARD assay. The genes in the GPS were therefore compared to the DE transcripts which revealed that 43 transcripts were found in both lists. This demonstrated that almost 22% of the genes in the GPS were differentially expressed between the cell lines. A comparison between the results in the phenotype and the RNA-seq data was performed to investigate the analysis methods and possibly give more validity to the findings. The panel of biomarkers and their corresponding genes were compared in a concordance analysis. The comparison was performed as an evaluation of a classification task with the groups significantly higher, significantly lower or not different in the MUTZ-3 compared to SenzaCell. The analysis resulted in a Cohens Kappa value of 0.44, suggesting concordance between the two methods, see expression for each marker in Table 1. 8 of the 10 surface markers that showed an increased expression also showed an increased expression in the RNAseq analysis. CD54 shows an increased gene expression in MUTZ- 3 which is opposed to the surface marker expression. The gene for TLR2 is not called as differentially expressed. 8 of the 14 surface markers that were not call significant did not have differentially expressed genes either. The gene expression levels for the remaining 6 markers were however found to be differentially expressed. CD34 was the only marker that was found to have significantly lower expression levels in the MUTZ-3 in both transcription levels and surface expression. HLA-DR was left out of this comparison due to its complex genetics. Table 4. Significantly different signaling pathways from SPIA after p-value correction using the Bonferroni method. The global p-values calculated by SPIA considers both the number of genes affected in the pathway and the perturbation of the signaling pathway. [Image disponible dans le document PDF, Image available in the PDF document] Functional analysis MUTZ-3 and SenzaCell's ability to distinguish skin sensitizers when analyzing the expression of the genes in the GARD prediction signature (GPS) after chemical exposure was assessed by using the cells in the well-established assay workflow. 2- hydroxyethylacrylate and DNCB were used to stimulate the cells and an unstimulated sample was used as negative control. RNA was quantified and the samples were classified using a SVM model trained on genetic profiles from SenzaCell. The chemicals were correctly classified as sensitizers and the unstimulated sample as non-sensitizer using both MUTZ-3 and SenzaCell, Figure 6. Further on, the prediction pattern, where 2- hydroxyethylacrylate has a higher prediction value than DNCB, is similar for MUTZ-3 as to what is obtained with SenzaCell. Discussion Allergic contact dermatitis is a condition with increasing prevalence that causes significant costs for society. Contact with skin sensitizers can trigger an immune response to attack the complexes that are formed between the chemical and biomolecules, resulting in an attack on healthy tissue (1). Assessment of a chemicals' ability to induce ACD is important to reduce the number of people that are affected by ACD. The gold standard for sensitization testing, the local lymph node assay (LLNA) (33), rely on animal testing and is being phased out by more ethical in vitro assays (6, 7, 34). The GARD assay is an in- vitro assay that distinguishes between sensitizers and non-sensitizers by analyzing the gene expression of the genes in the GARD prediction signature. The transcripts are isolated from a dendritic cell-like cell line that has been exposed to test chemicals. The assay relies on the innate decision making of the cell line to recognize sensitizers and adapt its gene expression, making it possible to quantify the changes and learn to recognize sensitizers (9). MUTZ-3 and SenzaCell are suitable cells for this task due their ability to resemble dendritic cells, which are important for recognizing antigens and orchestrate immune responses... SenzaCell was compared to MUTZ-3 by characterizing their phenotype, genotype and assessing the cell line's ability to distinguish sensitizers from non-sensitizers when used in the assay. The expression levels of a panel of surface markers were determined for both cell lines. The results demonstrated that 12 out of 26 surface markers had a different expression levels in MUTZ-3 compared to SenzaCell. A hierarchical clustering algorithm with bootstrapping also showed the possibility to group the cell lines into different stable clusters, implying that the cell lines are more similar to themselves than the other cell line over the course of the experiments. The surface markers that had higher expression values in MUTZ-3 were CD1a, CD11b, CD14, CD15, CD32, CD40, CD64, TLR2 and TLR4 while CD34, CD54 and HLA-DR had lower expression values. MUTZ-3 cells can, based on CD14 and CD34 expression, be divided into three subpopulations; CD34<com:Sup>+< / com:Sup> CD14<com:Sup>-< / com:Sup>, CD34<com:Sup>-< / com:Sup> CD14<com:Sup>-< / com:Sup> and CD34<com:Sup>-< / com:Sup> CD14<com:Sup>+< / com:Sup>. Previous analysis of the populations revealed that the CD34<com:Sup>+< / com:Sup> CD14<com:Sup>-< / com:Sup> is the proliferating population which give rise to the other populations (35). Some of the differences between SenzaCell and MUTZ-3 could therefore possibly be explained by the differences between the subpopulations, e.g. the increased amount of CD14 <com:Sup>+< / com:Sup> cells in MUTZ-3 could possibly explain the increased CD11b <com:Sup>+< / com:Sup> expression (35). However, considering the available data, the different levels in expression cannot be explained solely due to different sizes of the subpopulations. CD1a is expressed in both cell lines, which has preciously not been recorded in undifferentiated MUTZ-3 (8, 35, 36). The expression of CD1a could therefore indicate differentiation of the MUTZ-3 cells towards a more dendritic cell like phenotype. MUTZ-3 displayed a larger population of CD1a positive cells, which could indicate that it is more differentiated than SenzaCell. Evidence that further implies that MUTZ-3 could be more differentiated comes from the increased CD40 expression, which is a marker that increases in expression as cells differentiate towards a DC phenotype (37). Although both CD1a and CD40 are expressed in higher levels in MUTZ-3, the expression of other surface markers show evidence of the contrary. HLA-DR is another marker whose expression has been shown to moderately increase with differentiation which is more expressed in SenzaCell, making it difficult to draw any conclusions regarding unequal levels of differentiation between the cell lines (37). Further on, neither of the cell lines' morphology exhibits the characteristic dendrites that are formed as MUTZ-3 differentiates (data not shown). Considering the roles of the surface markers that are differentially expressed, many are related to myeloid cell differentiation, e.g. the FC-gamma receptors CD32 and CD64 (38), the pathogen recognition receptors (PRR) TLR2 and TLR4 (39-41) or the carbohydrate adhesion molecule CD15 (42). This could indicate that there is some form of differentiation that is responsible for the observed differences; however the nature of the differentiation process is difficult to determine using only the obtained expression values. The whole genome sequencing was performed to compare the genomes of the cell lines and search for indications of genetic differences. The number of identified variants lie within the expected range as a typical person differs at 4.1 million to 5 million sites compared to the reference genome (43). Variants that were unique to either of the cell lines were identified and their predicted impacts were assessed. In total, 7,977 unique variants were discovered in the SenzaCell and 5,672 in MUTZ-3. Comparing the number of discovered unique variants to the number of common variants makes the observed differences seem small. However when filtering variants with low impact and assessing variants predicted to have a moderate or high impact, the situation was reversed. 14 variants were discovered in SenzaCell and 28 mutations in MUTZ-3. One of the reasons for these results could be due to the insensitivity of the method used to identify variants. Whole genome sequencing is a high throughput method which generates billions of reads. The process of transforming the reads into interpretable results is difficult and an ongoing challenge. However, if assuming that the discovered variants are unique to the cell lines and not the artifacts from detection, they could be the product of other biological processes. Genetic differences can be caused by selective pressure as the cell lines grow. If MUTZ-3 contains subpopulations with different variants in its genome, it is possible that some of them have been lost in SenzaCell. Genetic heterogeneity has previously been shown in cell lines (44). Another possibility is that MUTZ-3 has been expanded in parallel to SenzaCell, which could have generated the discovered variants. A parallel expansion of MUTZ-3 cell line could result in finding unique variants that are absent in the SenzaCell cells, but would require the mutations to be of high or moderate impact with higher frequency. A continued parallel expansion could possibly introduce additional differences between the cell lines. The biological processes that were mapped to the genes predicted to be impacted by the mutations are general terms and difficult to draw functional conclusions from. This is made even harder when considering the impact that a mutation has, e.g. the effect of a missense variant where an amino acid in the resulting protein is changed to another amino acid. However, studying the gene lists reveals interesting variants. The high impact variant found in MUTZ-3 in the MYB gene could be a relevant finding. The MYB is an identified oncogene that normally has important functions in the regulation of stem- and progenitor cells (45). Another interesting observation is the mutation in the WISP1 gene, also in the MUTZ-3. WISP1 functions in the WNT signaling pathways which has important roles in mediating cell-cell interactions and stem cell regulation and control (46-48). Both of these mutations could be important for the function and regulation of the cell lines, and the lack of these variants in SenzaCell could have a functional impact. Analysis of the cell transcriptomes were performed by quantification of transcription levels using RNA-seq during ordinary cultivation. A comparison of the expression levels revealed that 3644 transcripts were differentially expressed, which is close to 10% of all the transcripts that were analyzed after removing zero count transcripts. The high number of differentially expressed genes suggests that large differences between the cell lines can be observed at molecular level. An overrepresentation test and a topological pathway analysis were performed to get a better understanding of the potential impacts that the identified genes could have on the cells. 94 biological process GO terms were identified as over- or underrepresented amongst the identified transcripts. Due to the comparative analysis of identifying differences between the cell lines, overrepresented terms are of the greatest importance. Underrepresented terms can be interesting in other types of analyses, e.g. to identify key biological processes necessary for cell function. However, most of the identified GO terms were overrepresented. To briefly mention some of the GO terms, myeloid leukocyte activation and leukocyte chemotaxis were identified as the biological processes with largest fold change between the expected and the observed number of transcripts. Both of these terms indicate response to external stimuli (49). Positive regulation of MAP kinase activity was also identified with many related GO terms. The MAP kinases are involved in signaling pathways that control important cellular processes such as cell differentiation, cell proliferation and cell death (50). Different inflammatory responses and immune processes were also identified as overrepresented, which could be of importance due to the functional role of SenzaCell in the GARD assay. Continuing the analysis of the RNA-seq data, a pathway analysis was performed to gain further knowledge about the differences between the cell lines. The pathway analysis discovered 19 signaling pathways that were significantly activated and 2 that were inhibited in the MUTZ-3 cells compared to SenzaCell. MAP kinase signaling pathway was identified as activated in MUTZ-3. MAP kinase activity was also identified as an overrepresented biological process, giving additional evidence of changes in cellular processes between the cell lines. NF-kappa B signaling is another interesting pathway that was discovered as activated, which is intimately linked to inflammatory responses (51). These observations together with the activated toll-like receptor signaling could be the result of an inflammatory response. The functional analysis showed that MUTZ-3 was able to produce predictions similar to what is achieved when using SenzaCell in the assay. The sensitizers DNCB and 2- hydroxyethylacrylate were correctly predicted as sensitizers by assessing the transcriptional levels of the genes in the GPS. The predicted decision values also showed a similar pattern between the two cell lines. The ability to separate the chemicals do however not directly give any measure of similarity. It is possible that the cells react similar to stimuli and that the GPS captures these changes well. To summarize the comparisons, we have completed a phenotypic analysis which revealed that 12 out of 26 surface markers were differentially expressed between MUTZ-3 and SenzaCell. Cluster analysis on the expression values forms two separate clusters which separates the cell lines. Whole genome sequencing identified more unique variants in the SenzaCell cell line when assessing all the discovered variants. When filtering out low impact variants, the MUTZ-3 cell lines contained 28 variants compared to 14 in the SenzaCell cell line. Some of the identified variants could have important impacts in the functions of the cells. The RNA-seq analysis found 3644 transcripts that were differentially expressed. An overrepresentation test and a pathway analysis revealed that many biological processes and signaling pathways were differentially activated. Finally, MUTZ- 3 and SenzaCell have been used in the GARD assay to evaluate their ability to recognize sensitizers and produce predictions. The classifications of the samples resulted in correct predictions for all the chemicals, indicating that both cell lines could be used in the assays, despite observed differences. In conclusion, we have identified numerous differences between SenzaCell and MUTZ-3 in phenotypic and genotypic analyses. Collectively the differences indicate that SenzaCell has unique expression of surface molecules and cellular functions, yet both cell lines can be used in the GARD assays. 10 Supplementary Table 1. List of the identified differentially expressed transcripts after DE analysis using DESeq2 and edgeR- [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000197937 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000134531 ENSG00000175471 ENSG00000184588 ENSG00000184371 ENSG00000177169 ENSG00000188725 ENSG00000157110 ENSG00000120875 ENSG00000163956 ENSG00000169442 ENSG00000164929 ENSG00000064989 ENSG00000137331 ENSG00000138185 ENSG00000250722 ENSG00000110324 ENSG00000131355 ENSG00000138449 ENSG00000131669 ENSG00000138772 ENSG00000169429 ENSG00000134463 ENSG00000070018 ENSG00000186431 ENSG00000138722 ENSG00000159496 ENSG00000198736 ENSG00000174059 ENSG00000109576 ENSG00000256771 ENSG00000058091 ENSG00000148468 ENSG00000145335 ENSG00000182557 ENSG00000107165 ENSG00000146070 ENSG00000149100 ENSG00000159339 ENSG00000108947 ENSG00000135387 ENSG00000168497 ENSG00000117461 ENSG00000214063 ENSG00000113389 ENSG00000163736 ENSG00000198848 ENSG00000127824 ENSG00000160161 ENSG00000121691 ENSG00000073737 ENSG00000122694 ENSG00000113273 ENSG00000140379 ENSG00000085265 ENSG00000039560 ENSG00000060982 ENSG00000135372 ENSG00000166401 ENSG00000178538 ENSG00000055118 ENSG00000144802 ENSG00000136315 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000049089 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000214455 ENSG00000151012 ENSG00000125430 ENSG00000147443 ENSG00000166326 ENSG00000257743 ENSG00000174837 ENSG00000167775 ENSG00000224940 ENSG00000089177 ENSG00000052126 ENSG00000164512 ENSG00000234493 ENSG00000197249 ENSG00000119686 ENSG00000187049 ENSG00000123095 ENSG00000186652 ENSG00000135838 ENSG00000130300 ENSG00000114439 ENSG00000140678 ENSG00000105088 ENSG00000197608 ENSG00000169247 ENSG00000154188 ENSG00000148943 ENSG00000174944 ENSG00000081189 ENSG00000178053 ENSG00000234147 ENSG00000186827 ENSG00000157404 ENSG00000140030 ENSG00000090674 ENSG00000198842 ENSG00000189190 ENSG00000121053 ENSG00000179776 ENSG00000164111 ENSG00000171049 ENSG00000086548 ENSG00000133195 ENSG00000023330 ENSG00000143515 ENSG00000160307 ENSG00000078081 ENSG00000100342 ENSG00000114013 ENSG00000100368 ENSG00000102554 ENSG00000101197 ENSG00000268758 ENSG00000184221 ENSG00000182487 ENSG00000223865 ENSG00000176788 ENSG00000171159 ENSG00000174403 ENSG00000115170 ENSG00000176340 ENSG00000115286 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000163606 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000121933 ENSG00000131979 ENSG00000143195 ENSG00000151320 ENSG00000171649 ENSG00000141526 ENSG00000108176 ENSG00000087303 ENSG00000163734 ENSG00000171502 ENSG00000105810 ENSG00000125910 ENSG00000155659 ENSG00000078902 ENSG00000165029 ENSG00000133805 ENSG00000226742 ENSG00000112294 ENSG00000251442 ENSG00000177606 ENSG00000188580 ENSG00000152082 ENSG00000175899 ENSG00000149131 ENSG00000164904 ENSG00000233452 ENSG00000166897 ENSG00000181409 ENSG00000196533 ENSG00000130702 ENSG00000197208 ENSG00000251400 ENSG00000160211 ENSG00000161921 ENSG00000171403 ENSG00000103569 ENSG00000078804 ENSG00000198018 ENSG00000121807 ENSG00000188822 ENSG00000104825 ENSG00000167996 ENSG00000006534 ENSG00000168685 ENSG00000110002 ENSG00000145916 ENSG00000175806 ENSG00000051523 ENSG00000117115 ENSG00000134569 ENSG00000188404 ENSG00000066468 ENSG00000143226 ENSG00000136193 ENSG00000066294 ENSG00000145390 ENSG00000182179 ENSG00000104904 ENSG00000204161 ENSG00000134460 ENSG00000110697 ENSG00000122861 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000051128 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000228695 ENSG00000134107 ENSG00000110841 ENSG00000187051 ENSG00000134070 ENSG00000183242 ENSG00000125503 ENSG00000104879 ENSG00000040531 ENSG00000150907 ENSG00000106123 ENSG00000135476 ENSG00000084234 ENSG00000151651 ENSG00000021645 ENSG00000055163 ENSG00000146232 ENSG00000122025 ENSG00000112715 ENSG00000126947 ENSG00000156587 ENSG00000182718 ENSG00000196914 ENSG00000125170 ENSG00000157350 ENSG00000187653 ENSG00000104093 ENSG00000166123 ENSG00000008394 ENSG00000182087 ENSG00000170946 ENSG00000138443 ENSG00000175130 ENSG00000079215 ENSG00000103363 ENSG00000187147 ENSG00000161671 ENSG00000183049 ENSG00000134184 ENSG00000091181 ENSG00000224397 ENSG00000183048 ENSG00000099624 ENSG00000141577 ENSG00000165659 ENSG00000169519 ENSG00000046604 ENSG00000162174 ENSG00000115738 ENSG00000125780 ENSG00000136630 ENSG00000148411 ENSG00000184164 ENSG00000116991 ENSG00000077238 ENSG00000173221 ENSG00000189120 ENSG00000139832 ENSG00000173542 ENSG00000116670 ENSG00000147955 ENSG00000135842 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000105404 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000117266 ENSG00000166352 ENSG00000081059 ENSG00000178860 ENSG00000127507 ENSG00000166432 ENSG00000149798 ENSG00000018280 ENSG00000133246 ENSG00000131634 ENSG00000143333 ENSG00000230400 ENSG00000092929 ENSG00000071655 ENSG00000133466 ENSG00000237440 ENSG00000155629 ENSG00000146094 ENSG00000168528 ENSG00000160255 ENSG00000115641 ENSG00000254726 ENSG00000167671 ENSG00000173402 ENSG00000173868 ENSG00000101188 ENSG00000110717 ENSG00000129925 ENSG00000144218 ENSG00000122970 ENSG00000205730 ENSG00000152582 ENSG00000154479 ENSG00000059728 ENSG00000100417 ENSG00000042753 ENSG00000138758 ENSG00000099804 ENSG00000169641 ENSG00000124334 ENSG00000196950 ENSG00000106034 ENSG00000168843 ENSG00000180257 ENSG00000154447 ENSG00000154930 ENSG00000076944 ENSG00000160883 ENSG00000213347 ENSG00000129235 ENSG00000183621 ENSG00000119865 ENSG00000204482 ENSG00000120156 ENSG00000166557 ENSG00000167851 ENSG00000256660 ENSG00000135631 ENSG00000011132 ENSG00000137135 ENSG00000272825 ENSG00000073169 ENSG00000159069 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000172380 ENSG00000157554 ENSG00000164087 ENSG00000131650 ENSG00000169744 ENSG00000162722 ENSG00000100284 ENSG00000130429 ENSG00000081041 ENSG00000164484 ENSG00000108091 ENSG00000197562 ENSG00000011422 ENSG00000130775 ENSG00000152818 ENSG00000243477 ENSG00000100242 ENSG00000162522 ENSG00000173272 ENSG00000137834 ENSG00000205978 ENSG00000153993 ENSG00000087448 ENSG00000149970 ENSG00000171045 ENSG00000091129 ENSG00000106701 ENSG00000074706 ENSG00000123989 ENSG00000227507 ENSG00000076555 ENSG00000128973 ENSG00000110046 ENSG00000144451 ENSG00000163959 ENSG00000183134 ENSG00000115306 ENSG00000116641 ENSG00000197329 ENSG00000001561 ENSG00000163694 ENSG00000185803 ENSG00000170293 ENSG00000172575 ENSG00000231991 ENSG00000122417 ENSG00000130312 ENSG00000180448 ENSG00000064961 ENSG00000088053 ENSG00000010327 ENSG00000184990 ENSG00000188486 ENSG00000127533 ENSG00000135940 ENSG00000167601 ENSG00000138119 ENSG00000174886 ENSG00000155307 ENSG00000183019 ENSG00000019582 ENSG00000140836 ENSG00000111679 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000135766 ENSG00000131446 ENSG00000100258 ENSG00000108001 ENSG00000171811 ENSG00000187699 ENSG00000135549 ENSG00000105963 ENSG00000040487 ENSG00000071242 ENSG00000167552 ENSG00000116663 ENSG00000131409 ENSG00000070882 ENSG00000164308 ENSG00000130881 ENSG00000091409 ENSG00000160949 ENSG00000167580 ENSG00000166341 ENSG00000196526 ENSG00000162437 ENSG00000095906 ENSG00000125657 ENSG00000011600 ENSG00000133612 ENSG00000224051 ENSG00000198171 ENSG00000167232 ENSG00000103326 ENSG00000166793 ENSG00000121621 ENSG00000023191 ENSG00000147459 ENSG00000105327 ENSG00000187800 ENSG00000182541 ENSG00000197016 ENSG00000078900 ENSG00000214655 ENSG00000112992 ENSG00000188921 ENSG00000149639 ENSG00000121413 ENSG00000109436 ENSG00000198133 ENSG00000114654 ENSG00000169991 ENSG00000099795 ENSG00000077454 ENSG00000078399 ENSG00000175756 ENSG00000160326 ENSG00000102096 ENSG00000205336 ENSG00000257176 ENSG00000134575 ENSG00000102780 ENSG00000185565 ENSG00000184117 ENSG00000171988 ENSG00000112077 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000111145 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000226979 ENSG00000146535 ENSG00000120885 ENSG00000149761 ENSG00000171631 ENSG00000008516 ENSG00000100365 ENSG00000186152 ENSG00000105373 ENSG00000165685 ENSG00000130706 ENSG00000121594 ENSG00000242802 ENSG00000165434 ENSG00000133275 ENSG00000179388 ENSG00000138061 ENSG00000163131 ENSG00000160685 ENSG00000118432 ENSG00000063241 ENSG00000104886 ENSG00000057252 ENSG00000184232 ENSG00000155252 ENSG00000162367 ENSG00000113721 ENSG00000121104 ENSG00000158825 ENSG00000118965 ENSG00000158869 ENSG00000185112 ENSG00000163840 ENSG00000140564 ENSG00000120129 ENSG00000169223 ENSG00000104368 ENSG00000197497 ENSG00000130733 ENSG00000167460 ENSG00000114480 ENSG00000164889 ENSG00000142875 ENSG00000149823 ENSG00000135916 ENSG00000167994 ENSG00000151746 ENSG00000233762 ENSG00000042980 ENSG00000188343 ENSG00000008517 ENSG00000163931 ENSG00000180316 ENSG00000204389 ENSG00000197766 ENSG00000121039 ENSG00000139793 ENSG00000179750 ENSG00000257335 ENSG00000142185 ENSG00000185198 ENSG00000154146 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000112149 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000104951 ENSG00000133065 ENSG00000160867 ENSG00000132510 ENSG00000027697 ENSG00000135046 ENSG00000153317 ENSG00000146858 ENSG00000130600 ENSG00000144040 ENSG00000152104 ENSG00000177674 ENSG00000156011 ENSG00000237604 ENSG00000146066 ENSG00000198075 ENSG00000127586 ENSG00000160957 ENSG00000130844 ENSG00000074842 ENSG00000133027 ENSG00000232368 ENSG00000102145 ENSG00000137801 ENSG00000149089 ENSG00000117245 ENSG00000226976 ENSG00000176783 ENSG00000126264 ENSG00000215417 ENSG00000164120 ENSG00000137968 ENSG00000124593 ENSG00000232203 ENSG00000109320 ENSG00000163322 ENSG00000168081 ENSG00000107819 ENSG00000099849 ENSG00000175701 ENSG00000204287 ENSG00000077984 ENSG00000126249 ENSG00000089351 ENSG00000151474 ENSG00000099800 ENSG00000110446 ENSG00000160191 ENSG00000161847 ENSG00000175463 ENSG00000165028 ENSG00000171051 ENSG00000186047 ENSG00000229671 ENSG00000131018 ENSG00000166927 ENSG00000130332 ENSG00000203306 ENSG00000163683 ENSG00000188566 ENSG00000251322 ENSG00000112667 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000164733 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000198399 ENSG00000198643 ENSG00000160791 ENSG00000128524 ENSG00000164897 ENSG00000141504 ENSG00000196865 ENSG00000185420 ENSG00000104880 ENSG00000247774 ENSG00000105374 ENSG00000166794 ENSG00000175414 ENSG00000006451 ENSG00000128268 ENSG00000197858 ENSG00000256234 ENSG00000062822 ENSG00000140284 ENSG00000073008 ENSG00000178217 ENSG00000168350 ENSG00000230195 ENSG00000244331 ENSG00000133030 ENSG00000149212 ENSG00000122515 ENSG00000099992 ENSG00000164088 ENSG00000196247 ENSG00000113303 ENSG00000063176 ENSG00000111912 ENSG00000169738 ENSG00000186010 ENSG00000167646 ENSG00000197442 ENSG00000137509 ENSG00000197312 ENSG00000184465 ENSG00000064225 ENSG00000179348 ENSG00000120262 ENSG00000185862 ENSG00000178802 ENSG00000127334 ENSG00000136231 ENSG00000183166 ENSG00000178605 ENSG00000178719 ENSG00000079432 ENSG00000108106 ENSG00000138639 ENSG00000166575 ENSG00000197506 ENSG00000211689 ENSG00000118046 ENSG00000169242 ENSG00000189013 ENSG00000169100 ENSG00000105701 ENSG00000198795 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000151882 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000172164 ENSG00000225674 ENSG00000147324 ENSG00000169231 ENSG00000105518 ENSG00000138764 ENSG00000100162 ENSG00000131797 ENSG00000167468 ENSG00000108639 ENSG00000104903 ENSG00000030582 ENSG00000116741 ENSG00000026950 ENSG00000106258 ENSG00000198677 ENSG00000148335 ENSG00000253159 ENSG00000120756 ENSG00000166896 ENSG00000169184 ENSG00000107872 ENSG00000105726 ENSG00000198721 ENSG00000163235 ENSG00000198053 ENSG00000174099 ENSG00000147168 ENSG00000138078 ENSG00000167513 ENSG00000103249 ENSG00000176533 ENSG00000175183 ENSG00000196458 ENSG00000227191 ENSG00000070718 ENSG00000166165 ENSG00000184897 ENSG00000132613 ENSG00000268734 ENSG00000141524 ENSG00000174469 ENSG00000245648 ENSG00000154099 ENSG00000102445 ENSG00000189089 ENSG00000127863 ENSG00000090581 ENSG00000119522 ENSG00000179085 ENSG00000261211 ENSG00000132334 ENSG00000108294 ENSG00000083799 ENSG00000102879 ENSG00000174233 ENSG00000123384 ENSG00000108984 ENSG00000138399 ENSG00000122359 ENSG00000141552 ENSG00000099203 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000163221 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000126790 ENSG00000116127 ENSG00000004059 ENSG00000047365 ENSG00000125798 ENSG00000268518 ENSG00000152556 ENSG00000182326 ENSG00000028277 ENSG00000094916 ENSG00000145494 ENSG00000102575 ENSG00000132846 ENSG00000020181 ENSG00000163393 ENSG00000167723 ENSG00000187116 ENSG00000105298 ENSG00000138801 ENSG00000125648 ENSG00000218175 ENSG00000167210 ENSG00000165983 ENSG00000160404 ENSG00000145391 ENSG00000162144 ENSG00000120949 ENSG00000065268 ENSG00000160213 ENSG00000124496 ENSG00000168476 ENSG00000106009 ENSG00000122741 ENSG00000112759 ENSG00000233355 ENSG00000079616 ENSG00000181619 ENSG00000106537 ENSG00000239713 ENSG00000105366 ENSG00000144485 ENSG00000170638 ENSG00000124785 ENSG00000182568 ENSG00000152689 ENSG00000166851 ENSG00000100154 ENSG00000115825 ENSG00000229425 ENSG00000100311 ENSG00000167578 ENSG00000169692 ENSG00000100003 ENSG00000198130 ENSG00000173327 ENSG00000197785 ENSG00000113448 ENSG00000002822 ENSG00000126254 ENSG00000238243 ENSG00000130560 ENSG00000144647 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000047932 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000147813 ENSG00000180992 ENSG00000167772 ENSG00000100271 ENSG00000122778 ENSG00000135341 ENSG00000110880 ENSG00000139132 ENSG00000132005 ENSG00000113749 ENSG00000105135 ENSG00000156030 ENSG00000250337 ENSG00000165804 ENSG00000184281 ENSG00000204160 ENSG00000234985 ENSG00000070190 ENSG00000137628 ENSG00000214688 ENSG00000214530 ENSG00000103496 ENSG00000151883 ENSG00000120784 ENSG00000133256 ENSG00000121680 ENSG00000126461 ENSG00000196268 ENSG00000196924 ENSG00000103335 ENSG00000145734 ENSG00000122482 ENSG00000003393 ENSG00000182220 ENSG00000005059 ENSG00000010310 ENSG00000236480 ENSG00000181381 ENSG00000001084 ENSG00000131016 ENSG00000244879 ENSG00000104852 ENSG00000132182 ENSG00000103266 ENSG00000104805 ENSG00000160226 ENSG00000099250 ENSG00000196172 ENSG00000124613 ENSG00000179241 ENSG00000164442 ENSG00000166311 ENSG00000147123 ENSG00000130726 ENSG00000163823 ENSG00000165633 ENSG00000172530 ENSG00000144026 ENSG00000097033 ENSG00000100241 ENSG00000135535 ENSG00000110367 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000043462 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000183690 ENSG00000147862 ENSG00000244482 ENSG00000254470 ENSG00000099814 ENSG00000163412 ENSG00000228300 ENSG00000198482 ENSG00000189283 ENSG00000148400 ENSG00000183011 ENSG00000163132 ENSG00000184967 ENSG00000122223 ENSG00000117480 ENSG00000075702 ENSG00000116017 ENSG00000126705 ENSG00000100290 ENSG00000253352 ENSG00000163701 ENSG00000165806 ENSG00000168906 ENSG00000150681 ENSG00000144369 ENSG00000121741 ENSG00000135272 ENSG00000263264 ENSG00000007944 ENSG00000176148 ENSG00000151835 ENSG00000171451 ENSG00000125652 ENSG00000084093 ENSG00000130592 ENSG00000136205 ENSG00000159267 ENSG00000107863 ENSG00000169398 ENSG00000106266 ENSG00000117450 ENSG00000204519 ENSG00000171476 ENSG00000050767 ENSG00000140287 ENSG00000144589 ENSG00000101290 ENSG00000167657 ENSG00000225892 ENSG00000116260 ENSG00000141873 ENSG00000075240 ENSG00000089639 ENSG00000105364 ENSG00000157637 ENSG00000101916 ENSG00000133250 ENSG00000135480 ENSG00000111331 ENSG00000110852 ENSG00000106804 ENSG00000148248 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000085644 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000107140 ENSG00000149781 ENSG00000101421 ENSG00000111077 ENSG00000119986 ENSG00000117226 ENSG00000093010 ENSG00000144681 ENSG00000168884 ENSG00000123131 ENSG00000233846 ENSG00000213753 ENSG00000003402 ENSG00000002330 ENSG00000162976 ENSG00000131759 ENSG00000145431 ENSG00000124588 ENSG00000121797 ENSG00000138336 ENSG00000027869 ENSG00000164292 ENSG00000234420 ENSG00000090776 ENSG00000197535 ENSG00000120217 ENSG00000077585 ENSG00000218418 ENSG00000146192 ENSG00000105401 ENSG00000133639 ENSG00000112787 ENSG00000135241 ENSG00000105464 ENSG00000163513 ENSG00000101220 ENSG00000186017 ENSG00000139405 ENSG00000079950 ENSG00000106624 ENSG00000111885 ENSG00000147804 ENSG00000087301 ENSG00000100263 ENSG00000128487 ENSG00000141522 ENSG00000183508 ENSG00000066933 ENSG00000174004 ENSG00000068323 ENSG00000144677 ENSG00000139318 ENSG00000259207 ENSG00000162636 ENSG00000069712 ENSG00000103494 ENSG00000148154 ENSG00000143537 ENSG00000187266 ENSG00000136490 ENSG00000087586 ENSG00000243679 ENSG00000140995 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000182500 ENSG00000186862 ENSG00000127540 ENSG00000162244 ENSG00000128185 ENSG00000111665 ENSG00000267287 ENSG00000148841 ENSG00000100239 ENSG00000131374 ENSG00000243449 ENSG00000163113 ENSG00000183751 ENSG00000167967 ENSG00000244485 ENSG00000118276 ENSG00000198931 ENSG00000257698 ENSG00000128016 ENSG00000142794 ENSG00000166225 ENSG00000182162 ENSG00000160256 ENSG00000167995 ENSG00000115275 ENSG00000198464 ENSG00000070669 ENSG00000174080 ENSG00000159692 ENSG00000166503 ENSG00000165156 ENSG00000007264 ENSG00000070404 ENSG00000171298 ENSG00000174938 ENSG00000157483 ENSG00000164284 ENSG00000164896 ENSG00000169972 ENSG00000235084 ENSG00000072274 ENSG00000101439 ENSG00000184470 ENSG00000094975 ENSG00000158156 ENSG00000119535 ENSG00000163536 ENSG00000084444 ENSG00000188994 ENSG00000103642 ENSG00000167394 ENSG00000095303 ENSG00000141994 ENSG00000169733 ENSG00000143578 ENSG00000171314 ENSG00000085563 ENSG00000178947 ENSG00000102221 ENSG00000143067 ENSG00000106003 ENSG00000170191 ENSG00000187792 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000110237 ENSG00000134986 ENSG00000103152 ENSG00000119979 ENSG00000132561 ENSG00000147416 ENSG00000144036 ENSG00000132356 ENSG00000154263 ENSG00000071794 ENSG00000142669 ENSG00000187231 ENSG00000129355 ENSG00000100024 ENSG00000196843 ENSG00000162413 ENSG00000100031 ENSG00000103245 ENSG00000171055 ENSG00000164506 ENSG00000197961 ENSG00000068305 ENSG00000107957 ENSG00000229953 ENSG00000184922 ENSG00000165716 ENSG00000111817 ENSG00000159335 ENSG00000213799 ENSG00000145491 ENSG00000148339 ENSG00000272405 ENSG00000138468 ENSG00000155660 ENSG00000105656 ENSG00000095932 ENSG00000107223 ENSG00000071859 ENSG00000078401 ENSG00000175137 ENSG00000130303 ENSG00000107890 ENSG00000114902 ENSG00000157538 ENSG00000186432 ENSG00000111670 ENSG00000168421 ENSG00000182903 ENSG00000184205 ENSG00000176871 ENSG00000233755 ENSG00000213463 ENSG00000137274 ENSG00000145911 ENSG00000181019 ENSG00000247746 ENSG00000166501 ENSG00000156017 ENSG00000214022 ENSG00000174502 ENSG00000063245 ENSG00000157540 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000182308 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000059915 ENSG00000170876 ENSG00000011304 ENSG00000101974 ENSG00000139289 ENSG00000150048 ENSG00000175048 ENSG00000198420 ENSG00000123870 ENSG00000143847 ENSG00000033327 ENSG00000205045 ENSG00000185262 ENSG00000149269 ENSG00000180336 ENSG00000125656 ENSG00000104055 ENSG00000173153 ENSG00000161981 ENSG00000059588 ENSG00000165312 ENSG00000167600 ENSG00000180667 ENSG00000138380 ENSG00000177595 ENSG00000128872 ENSG00000164828 ENSG00000014919 ENSG00000221926 ENSG00000100321 ENSG00000134444 ENSG00000184903 ENSG00000170340 ENSG00000133574 ENSG00000090006 ENSG00000168393 ENSG00000107175 ENSG00000261221 ENSG00000139323 ENSG00000217128 ENSG00000144136 ENSG00000147475 ENSG00000269640 ENSG00000179630 ENSG00000205339 ENSG00000023171 ENSG00000267416 ENSG00000196365 ENSG00000104635 ENSG00000155254 ENSG00000254004 ENSG00000173041 ENSG00000162511 ENSG00000162430 ENSG00000171466 ENSG00000007541 ENSG00000079691 ENSG00000112159 ENSG00000112972 ENSG00000162062 ENSG00000104856 ENSG00000106803 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000176595 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000007312 ENSG00000182095 ENSG00000065243 ENSG00000164713 ENSG00000105835 ENSG00000171522 ENSG00000149218 ENSG00000171634 ENSG00000197558 ENSG00000168116 ENSG00000169891 ENSG00000132718 ENSG00000176058 ENSG00000109265 ENSG00000134247 ENSG00000175155 ENSG00000005075 ENSG00000043591 ENSG00000108961 ENSG00000123607 ENSG00000172322 ENSG00000072310 ENSG00000141540 ENSG00000151458 ENSG00000109586 ENSG00000172243 ENSG00000197582 ENSG00000154743 ENSG00000169718 ENSG00000070540 ENSG00000224116 ENSG00000123136 ENSG00000152454 ENSG00000176853 ENSG00000134028 ENSG00000116704 ENSG00000250510 ENSG00000171757 ENSG00000198718 ENSG00000088727 ENSG00000172375 ENSG00000198252 ENSG00000174851 ENSG00000180879 ENSG00000127603 ENSG00000100599 ENSG00000126391 ENSG00000143079 ENSG00000196233 ENSG00000180573 ENSG00000157106 ENSG00000272068 ENSG00000106689 ENSG00000115155 ENSG00000244462 ENSG00000005020 ENSG00000169245 ENSG00000197603 ENSG00000272502 ENSG00000011028 ENSG00000155100 ENSG00000172428 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000130255 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000160972 ENSG00000164050 ENSG00000167004 ENSG00000135604 ENSG00000100364 ENSG00000164066 ENSG00000183688 ENSG00000142798 ENSG00000232499 ENSG00000172878 ENSG00000080345 ENSG00000138760 ENSG00000196209 ENSG00000177548 ENSG00000107614 ENSG00000123329 ENSG00000066422 ENSG00000188641 ENSG00000158286 ENSG00000175634 ENSG00000198502 ENSG00000025770 ENSG00000101079 ENSG00000148175 ENSG00000011009 ENSG00000123472 ENSG00000153071 ENSG00000086289 ENSG00000185359 ENSG00000004777 ENSG00000136250 ENSG00000108107 ENSG00000122042 ENSG00000244620 ENSG00000138688 ENSG00000150760 ENSG00000158104 ENSG00000067836 ENSG00000253710 ENSG00000166086 ENSG00000114737 ENSG00000170545 ENSG00000154134 ENSG00000125843 ENSG00000173486 ENSG00000097021 ENSG00000135506 ENSG00000126814 ENSG00000188002 ENSG00000143479 ENSG00000198707 ENSG00000025039 ENSG00000101096 ENSG00000149930 ENSG00000162946 ENSG00000154589 ENSG00000185269 ENSG00000196911 ENSG00000100084 ENSG00000163399 ENSG00000166579 ENSG00000197461 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000072210 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000185164 ENSG00000140365 ENSG00000164307 ENSG00000198168 ENSG00000032742 ENSG00000006712 ENSG00000135451 ENSG00000162300 ENSG00000110315 ENSG00000185347 ENSG00000160209 ENSG00000117000 ENSG00000171843 ENSG00000188313 ENSG00000197136 ENSG00000154358 ENSG00000173801 ENSG00000181045 ENSG00000085117 ENSG00000161267 ENSG00000196437 ENSG00000101665 ENSG00000142186 ENSG00000169083 ENSG00000100056 ENSG00000135821 ENSG00000145050 ENSG00000205302 ENSG00000233461 ENSG00000259758 ENSG00000155545 ENSG00000167562 ENSG00000070731 ENSG00000030419 ENSG00000231344 ENSG00000155438 ENSG00000154217 ENSG00000187912 ENSG00000160336 ENSG00000132688 ENSG00000136169 ENSG00000160087 ENSG00000153560 ENSG00000055609 ENSG00000156136 ENSG00000198858 ENSG00000168813 ENSG00000136813 ENSG00000114383 ENSG00000140264 ENSG00000173465 ENSG00000105516 ENSG00000059145 ENSG00000187325 ENSG00000182957 ENSG00000163935 ENSG00000064393 ENSG00000134982 ENSG00000154803 ENSG00000068366 ENSG00000133313 ENSG00000228612 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000133706 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000172572 ENSG00000183092 ENSG00000228974 ENSG00000128578 ENSG00000101464 ENSG00000136100 ENSG00000048471 ENSG00000100629 ENSG00000187994 ENSG00000213293 ENSG00000235162 ENSG00000081913 ENSG00000112078 ENSG00000133265 ENSG00000080189 ENSG00000140854 ENSG00000177311 ENSG00000144579 ENSG00000092621 ENSG00000105993 ENSG00000196712 ENSG00000142684 ENSG00000260065 ENSG00000138036 ENSG00000198846 ENSG00000136560 ENSG00000226137 ENSG00000132471 ENSG00000138600 ENSG00000166900 ENSG00000130402 ENSG00000091039 ENSG00000136381 ENSG00000229186 ENSG00000183340 ENSG00000109756 ENSG00000111801 ENSG00000135902 ENSG00000187193 ENSG00000088854 ENSG00000116871 ENSG00000090339 ENSG00000139266 ENSG00000102763 ENSG00000105671 ENSG00000105875 ENSG00000144455 ENSG00000198265 ENSG00000060138 ENSG00000154783 ENSG00000197258 ENSG00000141985 ENSG00000182048 ENSG00000213160 ENSG00000198146 ENSG00000051382 ENSG00000185504 ENSG00000100814 ENSG00000166598 ENSG00000111452 ENSG00000267533 ENSG00000198324 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000021355 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000115271 ENSG00000169131 ENSG00000227039 ENSG00000132603 ENSG00000173214 ENSG00000141854 ENSG00000169750 ENSG00000181656 ENSG00000166886 ENSG00000090857 ENSG00000145348 ENSG00000197045 ENSG00000112365 ENSG00000163947 ENSG00000159210 ENSG00000184924 ENSG00000181284 ENSG00000196544 ENSG00000224668 ENSG00000253797 ENSG00000160999 ENSG00000175467 ENSG00000126464 ENSG00000151702 ENSG00000005238 ENSG00000182141 ENSG00000125901 ENSG00000161551 ENSG00000117425 ENSG00000260174 ENSG00000105246 ENSG00000115956 ENSG00000171316 ENSG00000198113 ENSG00000184216 ENSG00000163644 ENSG00000179899 ENSG00000013275 ENSG00000224557 ENSG00000178150 ENSG00000132640 ENSG00000148429 ENSG00000167635 ENSG00000104529 ENSG00000205885 ENSG00000106992 ENSG00000135763 ENSG00000214425 ENSG00000015171 ENSG00000221968 ENSG00000142002 ENSG00000124181 ENSG00000196642 ENSG00000187535 ENSG00000225031 ENSG00000132286 ENSG00000110076 ENSG00000163635 ENSG00000157557 ENSG00000119685 ENSG00000216740 ENSG00000151576 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000129003 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000132589 ENSG00000185100 ENSG00000135404 ENSG00000101997 ENSG00000112685 ENSG00000049130 ENSG00000160392 ENSG00000170365 ENSG00000197245 ENSG00000229124 ENSG00000234389 ENSG00000112514 ENSG00000185640 ENSG00000070047 ENSG00000130856 ENSG00000092439 ENSG00000123213 ENSG00000204560 ENSG00000177380 ENSG00000198040 ENSG00000186792 ENSG00000152778 ENSG00000167261 ENSG00000136877 ENSG00000172336 ENSG00000088808 ENSG00000144591 ENSG00000117597 ENSG00000225101 ENSG00000104231 ENSG00000081386 ENSG00000124151 ENSG00000163344 ENSG00000182580 ENSG00000163050 ENSG00000146733 ENSG00000167695 ENSG00000141349 ENSG00000198315 ENSG00000140262 ENSG00000213281 ENSG00000013810 ENSG00000091106 ENSG00000167384 ENSG00000141456 ENSG00000182481 ENSG00000165813 ENSG00000197976 ENSG00000166595 ENSG00000185022 ENSG00000177666 ENSG00000264868 ENSG00000204623 ENSG00000103254 ENSG00000262879 ENSG00000152193 ENSG00000171681 ENSG00000118515 ENSG00000166484 ENSG00000074071 ENSG00000181555 ENSG00000104142 ENSG00000234883 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000100612 ENSG00000225339 ENSG00000115827 ENSG00000175489 ENSG00000105321 ENSG00000064763 ENSG00000186174 ENSG00000077150 ENSG00000122729 ENSG00000138286 ENSG00000077713 ENSG00000198182 ENSG00000085224 ENSG00000198258 ENSG00000150776 ENSG00000185800 ENSG00000228782 ENSG00000105220 ENSG00000123600 ENSG00000137166 ENSG00000173581 ENSG00000170801 ENSG00000173276 ENSG00000235008 ENSG00000111348 ENSG00000113811 ENSG00000176170 ENSG00000068394 ENSG00000170759 ENSG00000149948 ENSG00000184675 ENSG00000092148 ENSG00000047849 ENSG00000162591 ENSG00000125611 ENSG00000165494 ENSG00000125746 ENSG00000114812 ENSG00000137310 ENSG00000119714 ENSG00000198945 ENSG00000084207 ENSG00000078061 ENSG00000254023 ENSG00000168487 ENSG00000119599 ENSG00000186260 ENSG00000187244 ENSG00000167716 ENSG00000165046 ENSG00000149806 ENSG00000265798 ENSG00000185989 ENSG00000168209 ENSG00000125744 ENSG00000180509 ENSG00000059378 ENSG00000104964 ENSG00000133121 ENSG00000164970 ENSG00000114670 ENSG00000156515 ENSG00000198026 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000139508 ENSG00000204394 ENSG00000214021 ENSG00000116521 ENSG00000130311 ENSG00000089048 ENSG00000158006 ENSG00000160229 ENSG00000235106 ENSG00000085491 ENSG00000271533 ENSG00000100591 ENSG00000145907 ENSG00000115165 ENSG00000151304 ENSG00000225774 ENSG00000103966 ENSG00000102226 ENSG00000126602 ENSG00000188906 ENSG00000119333 ENSG00000107745 ENSG00000114026 ENSG00000163558 ENSG00000166171 ENSG00000119471 ENSG00000143624 ENSG00000125730 ENSG00000145332 ENSG00000197372 ENSG00000128309 ENSG00000186567 ENSG00000104133 ENSG00000162129 ENSG00000169251 ENSG00000154328 ENSG00000106723 ENSG00000148200 ENSG00000133816 ENSG00000135164 ENSG00000135845 ENSG00000166170 ENSG00000129277 ENSG00000124155 ENSG00000255521 ENSG00000087053 ENSG00000145545 ENSG00000164220 ENSG00000096717 ENSG00000176043 ENSG00000114062 ENSG00000059377 ENSG00000152229 ENSG00000175348 ENSG00000229676 ENSG00000163320 ENSG00000126217 ENSG00000146757 ENSG00000105849 ENSG00000010404 ENSG00000260997 ENSG00000049249 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000140396 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000146670 ENSG00000141219 ENSG00000186687 ENSG00000054523 ENSG00000113648 ENSG00000196646 ENSG00000144043 ENSG00000176619 ENSG00000110711 ENSG00000095951 ENSG00000188305 ENSG00000143669 ENSG00000064666 ENSG00000185052 ENSG00000078246 ENSG00000106261 ENSG00000225531 ENSG00000140006 ENSG00000127580 ENSG00000155099 ENSG00000122376 ENSG00000226745 ENSG00000126878 ENSG00000272216 ENSG00000119537 ENSG00000095383 ENSG00000104490 ENSG00000074621 ENSG00000163939 ENSG00000105618 ENSG00000144893 ENSG00000107719 ENSG00000007968 ENSG00000104218 ENSG00000090266 ENSG00000120832 ENSG00000154928 ENSG00000124789 ENSG00000009413 ENSG00000164902 ENSG00000036549 ENSG00000152061 ENSG00000139687 ENSG00000137563 ENSG00000183020 ENSG00000133136 ENSG00000271122 ENSG00000198298 ENSG00000085982 ENSG00000159110 ENSG00000145777 ENSG00000228234 ENSG00000085063 ENSG00000168283 ENSG00000153443 ENSG00000118058 ENSG00000117877 ENSG00000137494 ENSG00000089820 ENSG00000163464 ENSG00000168701 ENSG00000188868 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000146243 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000197165 ENSG00000260686 ENSG00000174600 ENSG00000197563 ENSG00000206560 ENSG00000163596 ENSG00000154025 ENSG00000169230 ENSG00000039650 ENSG00000108509 ENSG00000237984 ENSG00000122644 ENSG00000100647 ENSG00000260742 ENSG00000204165 ENSG00000128040 ENSG00000175203 ENSG00000164611 ENSG00000087299 ENSG00000002726 ENSG00000132953 ENSG00000170296 ENSG00000178980 ENSG00000144362 ENSG00000106400 ENSG00000182185 ENSG00000173166 ENSG00000113758 ENSG00000150712 ENSG00000198839 ENSG00000219626 ENSG00000011478 ENSG00000153879 ENSG00000166689 ENSG00000130812 ENSG00000110651 ENSG00000149485 ENSG00000089091 ENSG00000105879 ENSG00000163811 ENSG00000170144 ENSG00000173020 ENSG00000188747 ENSG00000196562 ENSG00000149541 ENSG00000166068 ENSG00000140718 ENSG00000215301 ENSG00000158792 ENSG00000175387 ENSG00000244682 ENSG00000183963 ENSG00000197483 ENSG00000185000 ENSG00000184481 ENSG00000100442 ENSG00000128159 ENSG00000049239 ENSG00000128581 ENSG00000163104 ENSG00000165283 ENSG00000214160 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000065183 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000120137 ENSG00000078124 ENSG00000083168 ENSG00000110066 ENSG00000174744 ENSG00000180488 ENSG00000196659 ENSG00000142459 ENSG00000204592 ENSG00000172009 ENSG00000130669 ENSG00000116337 ENSG00000116497 ENSG00000136628 ENSG00000111752 ENSG00000235437 ENSG00000039123 ENSG00000143751 ENSG00000111859 ENSG00000103174 ENSG00000243445 ENSG00000126267 ENSG00000213107 ENSG00000226986 ENSG00000182809 ENSG00000111731 ENSG00000107551 ENSG00000107902 ENSG00000241781 ENSG00000198909 ENSG00000171858 ENSG00000164338 ENSG00000228305 ENSG00000161813 ENSG00000137522 ENSG00000067533 ENSG00000173275 ENSG00000165959 ENSG00000100075 ENSG00000104946 ENSG00000156976 ENSG00000129515 ENSG00000124164 ENSG00000099194 ENSG00000267796 ENSG00000188976 ENSG00000111775 ENSG00000085514 ENSG00000082074 ENSG00000136643 ENSG00000198642 ENSG00000029725 ENSG00000129317 ENSG00000076928 ENSG00000104131 ENSG00000141582 ENSG00000124813 ENSG00000125970 ENSG00000103994 ENSG00000172840 ENSG00000169221 ENSG00000213820 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000157693 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000113407 ENSG00000140105 ENSG00000162441 ENSG00000171241 ENSG00000226721 ENSG00000130338 ENSG00000137965 ENSG00000166439 ENSG00000171291 ENSG00000188647 ENSG00000075945 ENSG00000213402 ENSG00000266282 ENSG00000147679 ENSG00000171940 ENSG00000174903 ENSG00000109466 ENSG00000103226 ENSG00000260336 ENSG00000204525 ENSG00000164604 ENSG00000233137 ENSG00000178149 ENSG00000244038 ENSG00000164631 ENSG00000203880 ENSG00000137275 ENSG00000138757 ENSG00000265206 ENSG00000133561 ENSG00000136270 ENSG00000146410 ENSG00000052795 ENSG00000102317 ENSG00000139637 ENSG00000128050 ENSG00000115216 ENSG00000088298 ENSG00000167987 ENSG00000167536 ENSG00000116984 ENSG00000181135 ENSG00000113658 ENSG00000105011 ENSG00000186283 ENSG00000167658 ENSG00000086200 ENSG00000117602 ENSG00000273142 ENSG00000131748 ENSG00000168061 ENSG00000169018 ENSG00000096746 ENSG00000198373 ENSG00000248866 ENSG00000118482 ENSG00000113070 ENSG00000126903 ENSG00000080823 ENSG00000248530 ENSG00000083535 ENSG00000141068 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000187954 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000167565 ENSG00000125484 ENSG00000170266 ENSG00000183484 ENSG00000176018 ENSG00000100330 ENSG00000197779 ENSG00000204131 ENSG00000156873 ENSG00000246985 ENSG00000145725 ENSG00000167850 ENSG00000096872 ENSG00000214181 ENSG00000146425 ENSG00000118454 ENSG00000170396 ENSG00000217835 ENSG00000107290 ENSG00000101216 ENSG00000136261 ENSG00000137700 ENSG00000160813 ENSG00000013523 ENSG00000184545 ENSG00000138594 ENSG00000062725 ENSG00000072958 ENSG00000169032 ENSG00000132274 ENSG00000104689 ENSG00000237181 ENSG00000185261 ENSG00000251667 ENSG00000167114 ENSG00000110799 ENSG00000126777 ENSG00000221930 ENSG00000173653 ENSG00000128590 ENSG00000168038 ENSG00000123552 ENSG00000166963 ENSG00000073111 ENSG00000170006 ENSG00000172339 ENSG00000196954 ENSG00000121289 ENSG00000163634 ENSG00000108510 ENSG00000074935 ENSG00000181826 ENSG00000043514 ENSG00000086730 ENSG00000103591 ENSG00000134824 ENSG00000213523 ENSG00000105486 ENSG00000158711 ENSG00000163156 ENSG00000142156 ENSG00000139624 ENSG00000231007 [Image disponible dans le document PDF, Image available in the PDF document] ENSG00000177888 ENSG00000187742 ENSG00000104915 ENSG00000164440 ENSG00000237819 ENSG00000131188 ENSG00000111877 ENSG00000004478 ENSG00000121152 ENSG00000120800 ENSG00000170949 ENSG00000092140 ENSG00000254244 ENSG00000159423 ENSG00000267889 ENSG00000151233 ENSG00000062370 ENSG00000164134 ENSG00000169299 ENSG00000198429 ENSG00000120899 ENSG00000141564 ENSG00000232626 ENSG00000038358 ENSG00000177030 ENSG00000115421 ENSG00000138439 ENSG00000064703 ENSG00000065526 ENSG00000103168 ENSG00000101017 ENSG00000112996 ENSG00000165671 ENSG00000140988 ENSG00000072736 ENSG00000132326 ENSG00000112234 ENSG00000125686 ENSG00000177374 ENSG00000225791 ENSG00000108468 ENSG00000257497 ENSG00000178999 ENSG00000135077 ENSG00000272093 ENSG00000119403 ENSG00000151067 ENSG00000197498 ENSG00000198598 ENSG00000164691 ENSG00000101126 ENSG00000163611 ENSG00000167965 ENSG00000169957 ENSG00000197013 ENSG00000165209 ENSG00000173141 ENSG00000179526 ENSG00000198019 ENSG00000147130 ENSG00000243364 ENSG00000127995 [Image disponible dans le document PDF, Image available in the PDF document] 5 Supplementary Table 2. GO biological processes identified as overrepresented in an overrepresentation analysis using the DE transcripts. The presented GO terms were called significant with a Bonferroni corrected P-value below 0.05. The corrected p-values are reported below. Number of mapped IDs from reference: 14774, unmapped IDs from reference: 12854; number of mapped IDs from DE transcripts: 3298, unmapped IDs from DE transcripts: 346. [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] EXAMPLE 2 The SenzaCell cell line may also be used together with a genomic biomarker signature for classification of respiratory sensitizers using the GARD platform, i.e. for identifying agents capable of inducing respiratory sensitization in a mammal. The methods may be performed in line with the methodology discussed in the functional analysis section of Example 1 above for identifying skin sensitizers but adapted to use the biomarker signature of Table B and / or Table C below. See also the detailed methodology described specifically for identifying agents capable of inducing respiratory sensitization described in WO 2013 / 160882; WO 2016 / 083604; and Forreryd et al. (2015) Prediction of chemical Respiratory sensitizers using GARD, a novel in vitro assay based on a genomic biomarker signature. PLoS One 10(3)). Table B "Core", "preferred" and "optional" biomarkers from the GARD Respiratory Prediction Signature. [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] Table B. Genes are annotated with Entrez Gene ID where found (www.ncbi.nlm.nih.gov / gene). The Affymetrix Probe Set ID for the Human ST 1.0 Array are provided. The validation call frequency (%) is the occurrence of each gene in the 20 Validation Biomarker Signatures obtained during cross- validation. Table C Table C(i) – Core biomarkers [Image disponible dans le document PDF, Image available in the PDF document] 5 [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] . [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] . [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] The table shows predictor genes in GRPS, identified by one-way ANOVA p-value filtering and Backward elimination. When possible, the Ensembl transcript ID was used as gene identifier. The Affymetrix Probe Set ID for the Human ST 1.0 Array are provided. <com:Sup>1< / com:Sup>Validation call frequency (%) describes the occurrence of each predictor transcript among the 20 biomarker signatures obtained by cross validation. EXAMPLE 3 The SenzaCell cell line may also be used for classification of the potency of skin sensitizers using the GARD platform, i.e. for determining the skin sensitizing potency of test agents. Such methods may be performed in line with those described in the functional analysis section of Example 1 above for identifying skin sensitizers but adapted to use the biomarker signature of Table D in order to determine potency. See also the specific methodology described in detail in Zeller et al. (2017) The GARD platform for potency assessment of skin sensitizing chemicals. ALTEX Online first published April 12, 2017, version 2, and also described in WO 2017 / 162773. [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] EXAMPLE 4 The SenzaCell cell line may also be used for identifying proteins which are allergenic in a mammal. The methods may be performed in line with the functional analysis section of Example 1 above for identifying skin sensitizers but adapted to use the biomarker signature of Table E in order to identify allergenic proteins. See also the methodology described in Zeller et al. An alternative biomarker-based approach for the prediction of proteins known to sensitize the respiratory tract. Toxicol In Vitro, 2017 Oct 7;46:155-162. A possible method of performing allergenic predictions on proteins is provided as follows. It is based on the GARD Protein Allergen Prediction Signature of Table E (herein referred to as "GARD PAPS"). The readout of GARD is a set of genomic predictors, referred to as the GARD Prediction Signature (GPS). The genetic material of the cells are isolated from cell samples stimulated with the test substances. The transcriptional levels of the GARD PAPS are quantified and compared to a reference data set by the use of multivariate statistical prediction models. Each sample is assigned a decision value based on its transcriptional levels of the GARD PAPS, as measured by Affymetrix microarray technology. Final predictions are based on the mean value from biological triplicate samples. All proteins are screened for cytotoxic effects and the GARD input concentration established for each protein. LPS may be used as a negative control, ensuring that observed signals generated by samples are not due to endotoxin contaminants. Endotoxin contents of the samples may be quantified using a LAL test. The LPS concentration used as a negative control may be set to correspond to the highest endotoxin concentration present in a sample. All test proteins and substances are assayed in biological triplicates. All replicates of test substances are assigned decision values using the GARD PAPS prediction model, as described (see materials and methods below). Materials & Methods The comprehensive materials and methods for the GARD testing strategy, used to generate data according to this example, is included below. Deviations from standard protocols The cytotoxic effects of the test proteins may be monitored in the concentration range 1- 25 μg / ml. 25 μg / ml may be used as the GARD input concentration. When stimulating the cells with the test substances, the proteins may first be dissolved in PBS to a concentration of 1000 µg / ml. 50 µl of the dissolved proteins then added to 1.95 ml of seeded cells. LPS may be diluted in PBS to a final concentration of 0.1 µg / ml and 2 µl added to 1.998 ml of cell suspension. The cells are stimulated for 24 h after which they are lysed in TRIzol reagent. RNA is purified, labeled and hybridized to Affymetrix arrays. The quantified transcription levels are single chain array normalized (SCAN) and the GARD PAPS extracted from the data set. Unstimulated samples, from the test samples and the reference samples used to build the prediction model, may be used to remove batch effects between data sets. Final classifications are made using a support vector machine (SVM) which had been trained on the reference samples used to establish the GARD PAPS. Cell line maintenance and seeding of cells for stimulation The SenzaCell cell line may be maintained in <com:Math><semantics>α<annotation encoding="application / x-tex">\alpha< / annotation>< / semantics>< / com:Math>-MEM (Thermo Scientific Hyclone, Logan, UT) supplemented with 20% (volume / volume) fetal calf serum (Life Technologies, Carlsbad, CA) and 40 ng / ml rhGM-CSF (Bayer HealthCare Pharmaceuticals, Seattle, WA), as described (Johansson et al., 2011). A media change during expansion is performed every 3-4 days, or when cell-density exceeds 5-600.000 cells / ml. Proliferating progenitor cells are used for the assay, with no further differentiation steps applied. During media exchange, cells are counted and suspended to 200.000 cells / ml. Working stocks of cultures are grown for a maximum of 20 passages or two months after thawing. For chemical stimulation of cells, 1.8 ml is seeded in 24-well plates at a concentration of 222.000 cells / ml. The compound to be used for stimulation is added in a volume of 200 µl, diluting the cell density to 200.000 cells / ml during incubation. Phenotypic analysis Prior to any chemical stimulation, a qualitative phenotypic analysis is performed to ensure that proliferating cells are in an immature stage. All cell surface staining and washing steps are performed in PBS containing 1% BSA (w / v). Cells are incubated with specific mouse monoclonal antibodies (mAbs) for 15 min at 4°C. The following mAbs are used for flow cytometry: FITC-conjugated CD1a (DakoCytomation, Glostrup, Denmark), CD34, CD86, and HLA-DR (BD Biosciences, San Diego, CA), PE-conjugated CD14 (DakoCytomation), CD54 and CD80 (BD Biosciences). Mouse IgG1, conjugated to FITC or PE are used as isotype controls (BD Biosciences) and propidium iodide (PI) (BD Biosciences) is used to assess cell viability. FACSDiva software is used for data acquisition with FACSCanto II instrument (BD Bioscience). 10,000 events are acquired, gates are set based on light scatter properties to exclude debris and non-viable cells, and quadrants are set according to the signals from isotype controls. Further data analysis is performed, using FCS Express V3 (De Novo Software, Los Angeles, CA). For a reference phenotype of unstimulated cells, see Johansson et al., 2011. Chemical handling and assessment of cytotoxicity All chemicals are stored according to instructions from the supplier, in order to ensure stability of compounds. Chemicals are dissolved in water when possible or DMSO for hydrophobic compounds. As many chemicals will have a toxic effect on the cells, cytotoxic effects of test substances are monitored. Some chemicals are poorly dissolved in cell media; therefore the maximum soluble concentration is assessed as well. The chemical that is to be tested is titrated to concentrations ranging from 1 µM to the maximum soluble concentration in cell media. For freely soluble compounds, 500 µM is set as the upper end of the titration range. For cell stimulations, chemicals are dissolved in its appropriate solvent as 1000x stocks of target in-well concentration, called stock A. A 10x stock, called stock B, is prepared by taking 10 µl of stock A to 990 µl of cell media. 200 µl of stock B is then added to the wells containing 1.8 ml seeded cells. For the samples dissolved in DMSO, the in-well concentration of DMSO will thus be 0.1%. Following incubation for 24h at 37°C and 5% CO2, harvested cells are stained with PI and analyzed with a flow cytometer. Pl-negative cells are defined as viable, and the relative viability of cells stimulated with each concentration in the titration range is calculated as [Image disponible dans le document PDF, Image available in the PDF document] For toxic compounds, the concentration yielding 90% relative viability (Rv90) is used for the GARD assay, the reason being that this concentration demonstrates bioavailability of the compound used for stimulation, while not impairing immunological responses. For non- toxic compounds, a concentration of 500 µM is used if possible. For non-toxic compounds that are insoluble at 500 µM in cell media, the highest soluble concentration is used. Whichever of these three criteria is met, only one concentration will be used for the genomic assay. The concentration to be used for any given chemical is termed the 'GARD' input concentration'. Chemical exposure of cells for GARD Once the GARD input concentration for chemicals to be assayed is established, the cells are stimulated again as described above, this time only using the GARD input concentration. All assessments of test substances are assayed in biological triplicates, performed at different time-points and using different cell cultures. Following incubation for 24h at 37°C and 5% CO2, cells from one well are lysed in 0.5ml TRIzol reagent (Life Technologies) and stored at -20°C until RNA is extracted. In parallel, a small sample of stimulated cells is taken for PI staining and analysis with flow cytometry, to ensure the expected relative viability of stimulated cells is reached. Preparation of benchmark controls In addition to any test substance(s) to be assayed within a campaign, a set of benchmark controls are performed, for the purpose of prediction model calibration and estimation of prediction performance. For details regarding benchmark controls used in each specific campaign, see the main document to which this appendix is attached. Isolation of RNA and GPS quantification using Nanostring nCounter system RNA isolation from lysed cells is performed using commercially available kits (Direct-Zol RNA MiniPrep, Zymo Research, Irvine, CA). Total RNA is quantified and quality controlled using BioAnalyzer equipment (Agilent, Santa Clara, CA). A total of 100ng of RNA is used as sample input in a hybridization assay with GPS specific reporter probe CodeSet (Nanostring, Seattle, WA). The hybridized RNA-CodeSet sample is prepared on chip using nCounter Prepstation and individual transcripts of the GPS is quantified using Nanostring Digital Analyzer (Nanostring). Data acquisition and normalization Raw data is exported from the Digital Analyzer and counts of individual transcripts of the GPS are single-chip normalized with a count per total counts algorithm. Normalized data consists of a S by V matrix, where S denotes the number of samples in the GARD campaign, and V denotes the number of quantified transcripts of the GPS. Data analysis - Generation of calibrated support vector machine decision values All further downstream analysis is performed using application-based software, developed in the open source statistical environment R. A support vector machine (SVM) is trained using historical data used for GPS establishment (Johansson et al., 2011). All samples from test substances and benchmark controls from the specific GARD campaign are predicted using the trained SVM, assigning each sample with a SVM decision value. The predictor performance is estimated by identification of the area under the receiver operating characteristic (ROC AUC) of the predicted class of benchmark controls. GARD classifications of test substance(s) The GARD prediction model is defined as follows: If the mean decision value of all available biological replicates of a test substance is greater than zero, the test substance is classified as a sensitizer. Scripts Listed below are details of the script, written in R code, which may be used to perform the method: # Required files: - GARD PAPS.R # - raw affymetrix files of test samples in subdir: raw affy / # - Annotation of the new data describing the unstimulated samples raw affy / annotation.rds # - Historical data stored in trainingset.rds # Load required dependencies source('~ / GARD PAPS.R') # Read Training Data train = readRDS('~ / trainingset.rds') # Read new data and annotations new data = read raw affy('~ / raw affy / *.CEL') new data ref = readRDS('~ / raw affy / annotation.rds') WO 2019 / 057977 PCT / EP2018 / 075829 # Normalize the new data normalized_data = normalize_train_test(train = train, test = new_data, test_reference = new_data_ref) 5 # Train model on historical data model = train_svm(normalized_data$train) # Predict New Samples predictions = predict_test_samples(model = model, 10 data=normalized_data$test) Table E [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] References 1. Peiser, M., T. Tralau, J. Heidler, A. M. Api, J. H. Arts, D. A. Basketter, J. English, T. L. Diepgen, R. C. Fuhlbrigge, A. A. Gaspari, J. D. Johansen, A. T. Karlberg, I. Kimber, J. P. Lepoittevin, M. Liebsch, H. I. Maibach, S. F. Martin, H. F. Merk, T. Platzek, T. Rustemeyer, A. Schnuch, R. J. Vandebriel, I. R. White, and A. Luch. 2012. Allergic contact dermatitis: epidemiology, molecular mechanisms, in vitro methods and regulatory aspects. Current knowledge assembled at an international workshop at BfR, Germany. Cellular and molecular life sciences: CMLS 69: 763-781. 2. Martin, S. F. 2012. Allergic contact dermatitis: xenoinflammation of the skin. Current opinion in immunology 24: 720-729. 3. Martin, S. F. 2015. New concepts in cutaneous allergy. Contact Dermatitis 72: 2- 10. 4. McFadden, J. P., P. Puangpet, D. A. Basketter, R. J. Dearman, and I. Kimber. 2013. Why does allergic contact dermatitis exist? Br J Dermatol 168: 692-699. 5. Thyssen, J. P., E. Gimenez-Arnau, J. P. Lepoittevin, T. Menne, A. Boman, and A. Schnuch. 2012. The critical review of methodologies and approaches to assess the inherent skin sensitization potential (skin allergies) of chemicals. Part I. Contact Dermatitis 66 Suppl 1: 11-24. 6. Reisinger, K., S. Hoffmann, N. Alépée, T. Ashikaga, J. Barroso, C. Elcombe, N. Gellatly, V. Galbiati, S. Gibbs, H. Groux, J. Hibatallah, D. Keller, P. Kern, M. Klaric, S. Kolle, J. Kuehnl, N. Lambrechts, M. Lindstedt, M. Millet, S. Martinozzi-Teissier, A. Natsch, D. Petersohn, I. Pike, H. Sakaguchi, A. Schepky, M. Tailhardat, M. Templier, E. van Vliet, and G. Maxwell. 2015. Systematic evaluation of non-animal test methods for skin sensitisation safety assessment. Toxicology in Vitro 29: 259-270. 7. Steiling, W. 2016. Safety Evaluation of Cosmetic Ingredients Regarding Their Skin Sensitization Potential. Cosmetics 3: 14. 8. Masterson, A. J., C. C. Sombroek, T. D. De Gruijl, Y. M. Graus, H. J. van der Vliet, S. M. Lougheed, A. J. van den Eertwegh, H. M. Pinedo, and R. J. Scheper. 2002. MUTZ- 3, a human cell line model for the cytokine-induced differentiation of dendritic cells from CD34+ precursors. Blood 100: 701-703. 9. Johansson, H., A.-S. Albrekt, C. A. K. Borrebaeck, and M. Lindstedt. 2013. The GARD assay for assessment of chemical skin sensitizers. Toxicology in Vitro 27: 1163- 1169. 10. Johansson, H., M. Lindstedt, A.-S. Albrekt, and C. A. Borrebaeck. 2011. A genomic biomarker signature can predict skin sensitizers using a cell-based in vitro alternative to animal tests. BMC Genomics 12: 1-19. 11. Geraghty, R. J., A. Capes-Davis, J. M. Davis, J. Downward, R. I. Freshney, I. Knezevic, R. Lovell-Badge, J. R. W. Masters, J. Meredith, G. N. Stacey, P. Thraves, and M. Vias. 2014. Guidelines for the use of cell lines in biomedical research. British Journal of Cancer 111: 1021-1046. 12. Dumont, J., D. Euwart, B. Mei, S. Estes, and R. Kshirsagar. 2015. Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives. Critical Reviews in Biotechnology: 1-13. 13. Kaur, G., and J. M. Dufour. 2012. Cell lines: Valuable tools or useless artifacts. Spermatogenesis 2: 1-5. 14. Hughes, P., D. Marshall, Y. Reid, H. Parkes, and C. Gelber. 2007. The costs of using unauthenticated, over-passaged cell lines: how much more data do we need? BioTechniques 43: 575, 577-578, 581-572 passim. 15. Team, R. C. 2015. R: A language and environment for statistical computing. {R Foundation for Statistical Computing. 16. Hennig, C. 2105. fpc: Flexible Procedures for Clustering. 17. McKenna, A., M. Hanna, E. Banks, A. Sivachenko, K. Cibulskis, A. Kernytsky, K. Garimella, D. Altshuler, S. Gabriel, M. Daly, and M. A. DePristo. 2010. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20. 18. Van der Auwera, G. A., M. O. Carneiro, C. Hartl, R. Poplin, G. del Angel, A. Levy- Moonshine, T. Jordan, K. Shakir, D. Roazen, J. Thibault, E. Banks, K. V. Garimella, D. Altshuler, S. Gabriel, and M. A. DePristo. 2013. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Current protocols in bioinformatics / editoral board, Andreas D. Baxevanis ... [et al.] 11: 11.10.11-11.10.33. 19. Cingolani, P., A. Platts, L. Wang le, M. Coon, T. Nguyen, L. Wang, S. J. Land, X. Lu, and D. M. Ruden. 2012. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly 6: 80-92. 20. Cingolani, P., V. M. Patel, M. Coon, T. Nguyen, S. J. Land, D. M. Ruden, and X. Lu. 2012. Using Drosophila melanogaster as a Model for Genotoxic Chemical Mutational Studies with a New Program, SnpSift. Frontiers in genetics 3: 35. 21. Carson, A. R., E. N. Smith, H. Matsui, S. K. Brækkan, K. Jepsen, J.-B. Hansen, and K. A. Frazer. 2014. Effective filtering strategies to improve data quality from population-based whole exome sequencing studies. BMC Bioinformatics 15: 1-15. 22. Mi, H., A. Muruganujan, J. T. Casagrande, and P. D. Thomas. 2013. Large-scale gene function analysis with the PANTHER classification system. Nat. Protocols 8: 1551- 1566. 23. Trapnell, C., L. Pachter, and S. L. Salzberg. 2009. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics (Oxford, England) 25: 1105-1111. 24. Li, H., B. Handsaker, A. Wysoker, T. Fennell, J. Ruan, N. Homer, G. Marth, G. Abecasis, and R. Durbin. 2009. The Sequence Alignment / Map format and SAMtools. Bioinformatics (Oxford, England) 25: 2078-2079. 25. Anders, S., P. T. Pyl, and W. Huber. 2015. HTSeq--a Python framework to work with high-throughput sequencing data. Bioinformatics (Oxford, England) 31: 166-169. 26. Robinson, M. D., D. J. McCarthy, and G. K. Smyth. 2010. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics (Oxford, England) 26: 139-140. 27. Love, M. I., W. Huber, and S. Anders. 2014. Moderated estimation of fold change and dispersion for RNA-Seq data with DESeq2. bioRxiv. 28. Tarca, A. L., S. Draghici, P. Khatri, S. S. Hassan, P. Mittal, J.-s. Kim, C. J. Kim, J. P. Kusanovic, and R. Romero. 2009. A novel signaling pathway impact analysis. Bioinformatics (Oxford, England) 25: 75-82. 29. Kanehisa, M., and S. Goto. 2000. KEGG: kyoto encyclopedia of genes and genomes. Nucleic acids research 28: 27-30. 30. Kanehisa, M., Y. Sato, M. Kawashima, M. Furumichi, and M. Tanabe. 2016. KEGG as a reference resource for gene and protein annotation. Nucleic acids research 44: D457- 462. 31. Kwiecien, R., A. Kopp-Schneider, and M. Blettner. 2011. Concordance Analysis: Part 16 of a Series on Evaluation of Scientific Publications. Deutsches Arzteblatt International 108: 515-521. 32. David Meyer, E. D., Kurt Hornik, Andreas Weingessel and Friedrich Leisch. 2015. e1071: Misc Functions of the Department of Statistics, Probability. 33. Haneke, K. E., R. R. Tice, B. L. Carson, B. H. Margolin, and W. S. Stokes. 2001. ICCVAM evaluation of the murine local lymph node assay. Data analyses completed by the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods. Regul Toxicol Pharmacol 34: 274-286. 34. Urbisch, D., A. Mehling, K. Guth, T. Ramirez, N. Honarvar, S. Kolle, R. Landsiedel, J. Jaworska, P. S. Kern, F. Gerberick, A. Natsch, R. Emter, T. Ashikaga, M. Miyazawa, and H. Sakaguchi. 2015. Assessing skin sensitization hazard in mice and men using non- animal test methods. Regulatory Toxicology and Pharmacology 71: 337-351. 35. Santegoets, S. J. A. M., A. J. Masterson, P. C. van der Sluis, S. M. Lougheed, D. M. Fluitsma, A. J. M. van den Eertwegh, H. M. Pinedo, R. J. Scheper, and T. D. de Gruijl. 2006. A CD34+ human cell line model of myeloid dendritic cell differentiation: evidence for a CD14+CD11b+ Langerhans cell precursor. Journal of Leukocyte Biology 80: 1337-1344. 36. Kim, K. D., S.-C. Choi, Y.-W. Noh, J. W. Kim, S.-G. Paik, Y. Yang, K. I. Kim, and J.-S. Lim. 0000. Impaired responses of leukemic dendritic cells derived from a human myeloid cell line to LPS stimulation. Exp Mol Med 38: 72-84. 37. Rasaiyaah, J., M. Noursadeghi, P. Kellam, and B. Chain. 2009. Transcriptional and functional defects of dendritic cells derived from the MUTZ-3 leukaemia line. Immunology 127: 429-441. 38. Fanger, N. A., K. Wardwell, L. Shen, T. F. Tedder, and P. M. Guyre. 1996. Type I (CD64) and type II (CD32) Fc gamma receptor-mediated phagocytosis by human blood dendritic cells. The Journal of Immunology 157: 541-548. 39. Iwasaki, A., and R. Medzhitov. 2004. Toll-like receptor control of the adaptive immune responses. Nat Immunol 5: 987-995. 40. Medzhitov, R., P. Preston-Hurlburt, and C. A. Janeway. 1997. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388: 394- 397. 41. Takeda, K., and S. Akira. 2005. Toll-like receptors in innate immunity. International Immunology 17: 1-14. 42. Gadhoum, S. Z., and R. Sackstein. 2008. Lewis x / CD15 expression in human myeloid cell differentiation is regulated by sialidase activity. Nature chemical biology 4: 751-757. 43. The Genomes Project, C. 2015. A global reference for human genetic variation. Nature 526: 68-74. 44. Nugoli, M., P. Chuchana, J. Vendrell, B. Orsetti, L. Ursule, C. Nguyen, D. Birnbaum, E. J. Douzery, P. Cohen, and C. Theillet. 2003. Genetic variability in MCF-7 sublines: evidence of rapid genomic and RNA expression profile modifications. BMC Cancer 3: 1-12. 45. Ramsay, R. G., and T. J. Gonda. 2008. MYB function in normal and cancer cells. Nature reviews. Cancer 8: 523-534. 46. Logan, C. Y., and R. Nusse. 2004. The Wnt signaling pathway in development and disease. Annual review of cell and developmental biology 20: 781-810. 47. Nusse, R. 2008. Wnt signaling and stem cell control. Cell research 18: 523-527. 48. Polakis, P. 2000. Wnt signaling and cancer. Genes & development 14: 1837-1851. 49. Consortium, T. G. O. 2015. Gene Ontology Consortium: going forward. Nucleic acids research 43: D1049-D1056. 50. Pearson, G., F. Robinson, T. Beers Gibson, B. E. Xu, M. Karandikar, K. Berman, and M. H. Cobb. 2001. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocrine reviews 22: 153-183. 51. Lawrence, T. 2009. The Nuclear Factor NF-kB Pathway in Inflammation. Cold Spring Harbor Perspectives in Biology 1: a001651.

Claims

Claims 1. A non-naturally occurring dendritic-like myeloid leukaemia cell according to ATCC Patent Deposit Designation PTA-123875.

2. A cell culture comprising a population of cells according to claim 1.

3. An in vitro method for identifying agents capable of inducing sensitization and / or allergenicity in a mammal comprising or consisting of the steps of: (a) exposing a population of the dendritic-like cells according to claims 1 or 2 to a test agent; and (b) measuring in the cells the expression of one or more biomarker(s) selected from the group defined in one or more of Tables A, B, C, D, E; wherein the expression in the cells of the one or more biomarkers measured in step (b) is indicative of the sensitizing and / or allergenic effect of the test agent.

4. An in vitro method for identifying agents capable of inducing sensitization of mammalian skin comprising or consisting of the steps of: (a) exposing a population of the dendritic-like cells according to claims 1 or 2 to a test agent; and (b) measuring in the cells the expression of one or more biomarker(s) selected from the group defined in Table A; wherein the expression in the cells of the one or more biomarkers measured in step (b) is indicative of the skin sensitizing effect of the test agent.

5. A method for identifying agents capable of inducing respiratory sensitization in a mammal comprising or consisting of the steps of: (a) exposing a population of the dendritic-like cells according to claims 1 or 2 to a test agent; and (b) measuring in the cells the expression of one or more biomarker(s) selected from the group defined in Table B or C; wherein the expression in the cells of the one or more biomarkers measured in step (b) is indicative of the respiratory sensitizing effect of the test agent.

6. A method for determining the skin sensitizing potency of an agent comprising or consisting of the steps of: (a) providing a population of the dendritic-like cells according to claims 1 or 2; (b) exposing the cells provided in step (a) to a test agent; and (c) measuring in the cells of step (b) the expression of one or more biomarkers selected from the group defined in Table D; wherein the expression of the one or more biomarkers measured in step (c) is indicative of the skin sensitizing potency of the test agent of step (b).

7. A method for identifying proteins which are allergenic in a mammal comprising or consisting of the steps of: (a) providing a population of the dendritic-like cells according to claims 1 or 2; (b) exposing the cells provided in step (a) to a test protein; and (c) measuring in the cells of step (b) the expression of one or more biomarkers selected from the group defined in Table E; wherein the expression of the one or more biomarkers measured in step (c) is indicative of the allergenicity of the test protein of step (b).

8. The method according to any one of claims 3-7 further comprising: (d) exposing a separate population of the dendritic-like cells according to claims 1 or 2 to one or more negative control agent that does not induce sensitization and / or allergy in a mammal; and (e) measuring in the cells of step (d) the expression of the one or more biomarkers measured in step (b) or (c) wherein the test agent is identified as a sensitizer and / or as allergenic in the event that the expression of the one or more biomarkers measured in step (e) differs from the expression of the one or more biomarkers measured in step (b) or (c).

9. The method according to any one of claims 3-8 further comprising: (f) exposing a separate population of the dendritic-like cells according to claims 1 or 2 to one or more positive control agent that induces sensitization and / or is allergenic in a mammal; and (g) measuring in the cells of step (f) the expression of the one or more biomarkers measured in step (b) or (c) wherein the test agent is identified as a sensitizer and / or as allergenic in the event that the expression of the one or more biomarkers measured in step (g) corresponds to the expression of the one or more biomarkers measured in step (b) or (c).

10. The method according to any one of claims 3-9 wherein steps (b), (c), (e) and / or (g) comprises measuring the expression of a nucleic acid molecule of one or more of the biomarkers, optionally wherein the nucleic acid molecule is a cDNA molecule or an mRNA molecule.

11. The method according to Claim 10 wherein measuring the expression of one or more of the biomarkers in steps (b), (c), (e) and / or (g) is performed using a method selected from the group consisting of Southern hybridisation, Northern hybridisation, polymerase chain reaction (PCR), reverse transcriptase PCR (RT-PCR), quantitative real-time PCR (qRT-PCR), nanoarray, microarray, macroarray, autoradiography and in situ hybridisation.

12. The method according to any one of Claims 10 to 11 wherein measuring the expression of one or more of the biomarkers in steps (b), (c), (e) and / or (g) is determined using a DNA microarray.

13. The method according to any one of claims 3-11 wherein measuring the expression of one or more of the biomarkers in steps (b), (c), (e) and / or (g) is performed using one or more binding moieties, each capable of binding selectively to a nucleic acid molecule encoding one of the biomarkers identified in one or more of Tables A-E, optionally wherein the one or more binding moieties each comprise or consist of a nucleic acid molecule, further optionally wherein the one or more binding moieties each comprise or consist of DNA, RNA, PNA, LNA, GNA, TNA or PMO.

14. The method according to Claim 13 wherein the binding moiety comprises a detectable moiety, optionally wherein the detectable moiety is selected from the group consisting of: a fluorescent moiety; a luminescent moiety; a chemiluminescent moiety; a radioactive moiety; and an enzymatic moiety.

15. The method according to any one of Claims 3 to 9 wherein steps (b), (c), (e) and / or (g) comprises or consists of measuring the expression of the protein of one or more of the biomarkers.

16. The method according to any one of claims 3-11 or 13-15 wherein steps (b), (c), (e) and / or (g) is performed using an array, optionally wherein the array is a bead-based array or a surface-based array, optionally wherein the array is selected from the group consisting of: macroarray; microarray; and nanoarray.

17. The method according to any one of claims 3-16 wherein steps (b), (c), (e) and / or (g) comprise or consist of measuring the expression of all of the biomarkers listed in any one of Tables A, B, C, D, and E.

18. Use of a population of dendritic-like cells according to claims 1 or 2 for determining the sensitizing effect and / or the allergenicity of a test agent.

19. An analytical kit comprising: (i) an array comprising one or more binding moieties; and (ii) one or more cell or a cell culture as defined in claims 1 or 2.

20. The analytical kit according to claim 19, wherein the kit further comprises: (iii) one or more control agents; and / or (iv) instructions for use.

21. An analytical kit for use in a method according any one of Claims 3-17 comprising: (i) an array comprising one or more binding moieties as defined in any one of claims 13-14; and (ii) one or more cell or a cell culture as defined in claims 1 or 2.

22. The analytical kit for use in a method according to claim 21, wherein the kit further comprises: (iii) one or more control agents; and / or (iv) instructions for use.